すべてわかるALS・運動ニューロン疾患

出版社： 中山書店
著者：
発行日： 2013-06-10
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784521734439
電子書籍版： 2013-06-10 （初版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

13,200 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

13,200 円(税込)

購入する

商品紹介

ALS(筋萎縮性側索硬化症)・運動ニューロン疾患は，神経変性疾患のなかでも治療やQOL面において最も厳しい疾患群であると言われているが，近年の病因遺伝子の発見やそれに基づく病態理解の進展には目覚ましいものがある．本書では，基礎・臨床を問わずにALS・運動ニューロン疾患をできるだけ多面的にとらえ，その現状の全体像と将来への展望を網羅的に論じている．

目次

  • すべてわかるALS・運動ニューロン疾患

    ―目次―

    I．運動系の構造と機能
    　運動ニューロンの構造と機能

    II．ALSの臨床像と診断
    　ALSの神経症候と鑑別診断
    　ALSの診断基準と疫学，自然歴
    　ALSの電気生理学的検査
    　ALSにおける運動ニューロン軸索興奮性の変化
    　ALSの画像所見
    　ALSにおける高次脳機能障害

    III．ALSと関連運動ニューロン疾患
    　孤発性ALS
    　ALSとFTLD
    　広汎性ALSの病理
    　家族性ALS
    　原発性側索硬化症
    　下位運動ニューロン障害型運動ニューロン疾患
    　球脊髄性筋萎縮症
    　脊髄性筋萎縮症
    　紀伊・グアムのALS
    　平山病（若年性一側上肢筋萎縮症）
    　Asidanの臨床的特徴

    IV．ALSの病態関連遺伝子と遺伝子変異
    　SOD1
    　ALS2/Alsin
    　TDP-43
    　FUS/TLS
    　Optineurin
    　ALSの関連遺伝子解析
    　　─ゲノムワイド関連解析の発展と現状を中心に
    　ALSの分子疫学と遺伝子解析の展望

    V．ALSの病態
    　グルタミン酸受容体のRNA編集異常
    　軸索輸送障害
    　ALSと酸化ストレス
    　グリア関連病態
    　RNA結合蛋白質（TDP-43,FUS）
    　オートファジー
    　ALSの動物モデル
    　ALSのバイオマーカー

    VI．ALSおよび関連運動ニューロン疾患の治療と介護
    　運動ニューロン疾患に対する再生医療の展望
    　ALSにおけるワクチン・抗体療法の開発
    　グリアを標的とした運動ニューロン疾患の治療戦略
    　球脊髄性筋萎縮症に対する分子標的治療法の開発
    　ALSの治療の現状と展望
    　　─臨床治験のレビューを含めて：米国を中心に
    　ALSに対する緩和医療
    　ALSの介護・呼吸器装着・栄養管理
    　ALSに対するリハビリテーション
    　災害医療における難病対策

    Case Study
    CASE　1　緩徐進行性の舌萎縮と四肢の
    　　　　　　運動・感覚障害，起立性低血圧を呈する68歳男性
    CASE　2　進行性の構音・嚥下障害，失語および
    　　　　　　書字障害を呈する70歳女性
    CASE　3　2か月前から飲み込みにくさ，呂律困難が出現した
    　　　　　　35歳男性
    CASE　4　頸椎症とALSの鑑別診断が問題の両上肢筋力低下の
    　　　　　　69歳女性
    CASE　5　幼少時から凹足があり，その後，四肢筋力低下，
    　　　　　　感覚障害，排尿障害が出現し，緩徐進行性の
    　　　　　　経過を示した41歳男性

    付録
    　ALS関連Webサイト

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 運動系の構造と機能

P.12 掲載の参考文献
1) Erlanger J, Gasser HS. Electrical Signs of Nervous Activity. Philadelphia : University of Pennsylvania Press ; 1937.
 
2) Bok ST. Das Ruckenmark. In : von Mollendorff W (editor). Handbuch der mikroskopischen Anatomie des Menschen. Bd. 4. Nervensystem 1 Teil. Nervengewebe, das peripherische Nervensystem, das Zentralnervensystem. Berlin : Springer ; 1928. pp.478-578.
 
3) Brodal A. Neurological Anatomy in Relation to Clinical Medicine, 3rd edition. New York : Oxford University Press ; 1981.
 
4) Kinoshita M, et al. Genetic dissection of the circuit for hand dexterity in primates. Nature 2012 ; 487 : 235-238.
PubMed
5) Lacroix S, et al. Bilateral corticospinal projections arise from each motor cortex in the macaque monkey : A quantitative study. J Comp Neurol 2004 ; 473 : 147-161.
PubMed
6) Guthrie S. Patterning and axon guidance of cranial motor neurons. Nat Rev Neurosci 2007 ; 8 : 859-871.
PubMed
7) Jessell TM. Neuronal specification in the spinal cord : Inductive signals and transcriptional codes. Nat Rev Genet 2000 ; 1 : 20-29.
PubMed
8) Lee SK, Pfaff SL. Transcriptional networks regulating neuronal identity in the developing spinal cord. Nat Neurosci 2001 ; 4 (Suppl) : 1183-1191.
 
9) Dasen JS, Jessell TM. Hox networks and the origins of motor neurons diversity. Curr Top Dev Biol 2009 ; 88 : 169-200.
PubMed

II. ALSの臨床像と診断

P.22 掲載の参考文献
1) Gubbay SS, et al. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. J Neurol 1985 ; 232 : 295-300.
PubMed
2) Caroscio JT, et al. Amyotrophic lateral sclerosis : Its natural history. Neurol Clin 1987 ; 5 : 1-8.
PubMed
3) Traynor BJ, et al. Clinical features of amyotrophic lateral sclerosis according to the EI Escorial and Airlie House diagnostic criteria : A population-based study. Arch Neurol 2000 ; 57 : 1171-1176.
 
4) Wilbourn AJ. The "split hand syndrome". Muscle Nerve 2000 ; 23 : 138.
PubMed
5) Ringholz GM, et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005 ; 65 : 586-590.
PubMed
6) Turner MR, et al. Pattern of spread and prognosis in lower limb-onset ALS. Amyotroph Lateral Scler 2010 ; 11 : 369-373.
PubMed
7) Gargiulo-Monachelli GM, et al. Regional spread pattern predicts survival in patients with sporadic amyotrophic lateral sclerosis. Eur J Neurol 2012 ; 19 : 834-841.
 
8) Polymenidou M, Cleveland DW. The seeds of neurodegeneration : Prion-like spreading in ALS. Cell 2011 ; 147 : 498-508.
PubMed
9) Sasaki S, Iwata M. An atypical form of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1999 ; 66 : 581-585.
PubMed
10) Hu MT, et al. Flail arm syndrome : A distinctive variant of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1998 ; 65 : 950-951.
PubMed
11) Katz JS, et al. Brachial amyotrophic diplegia : A slowly progressive motor neuron disorder. Neurology 1999 ; 53 : 1071-1076.
 
12) Chio A, et al. Phenotypic heterogeneity of amyotrophic lateral sclerosis : A population based study. J Neurol Neurosurg Psychiatry 2011 ; 82 : 740-746.
PubMed
13) Wijesekera LC, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 2009 ; 72 : 1087-1094.
PubMed
14) Patrikios JS. Contribution a l'Etude des Formes Cliniques et de l'Anatomie Pathologique de la Sclerose Laterale Amyotrophique. Paris : Paris University ; 1918.
 
15) Alema G, et al. On 3 cases of the pseudopolyneuritic form of amyotrophic lateral sclerosis. Anatomic and electromyographic study. J Neurol Sci 1967 ; 4 : 241-257.
PubMed
16) Keegan JJ. The cause of dissociated motor loss in the upper extremity with cervical spondylosis. J Neurosurg 1965 ; 23 : 528-536.
PubMed
17) Ikusaka M, et al. Progressive dysphagia due to adult Chiari I malformation mimicking amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1996 ; 60 : 357-358.
PubMed
P.29 掲載の参考文献
1) Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994 ; 124 Suppl : 96-107.
 
2) Brooks BR, et al. El Escorial revisited : Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000 ; 1 : 293-299.
 
3) 横山徹爾, 土井由利子. 平成20年患者調査による難病の受療状況データブック. 平成22年度厚生労働科学研究費補助金難治性疾患克服研究事業特定疾患の疫学に関する研究班 (研究代表者 : 永井正規), 2011.
 
4) Kihira T, et al. Changes in the incidence of amyotrophic lateral sclerosis in Wakayama, Japan. Amyotroph Lateral Scler Other Motor Neuron Disord 2005 ; 6 : 155-163.
PubMed
5) Doi Y, et al. Temporal trends and geographic clusters of mortality from amyotrophic lateral sclerosis in Japan, 1995-2004. J Neurol Sci 2010 ; 298 : 78-84.
PubMed
6) Cronin S, et al. Ethnic variation in the incidence of ALS : A systematic review. Neurology 2007 ; 68 : 1002-1007.
 
7) Byrne S, et al. Rate of familial amyotrophic lateral sclerosis : A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2011 ; 82 : 623-627.
PubMed
8) McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med 2010 ; 7 : 557-570.
PubMed
9) Haverkamp LJ, et al. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995 ; 118 (Pt 3) : 707-719.
 
10) Chio A, et al. Prognostic factors in ALS : A critical review. Amyotroph Lateral Scler 2009 ; 10 : 310-323.
 
11) 桃井浩樹ほか. 本邦における筋萎縮性側索硬化症の病勢経過-厚生省特定疾患神経変性疾患調査研究班調査より. 神経研究の進歩 2004 ; 48 : 133-144.
 
12) 木村文治ほか. 筋萎縮性側索硬化症100例の変遷. 臨床神経学 2003 ; 43 : 385-391.
 
13) Czaplinski A, et al. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis : Is the natural history of amyotrophic lateral sclerosis changing? Arch Neurol 2006 ; 63 : 1139-1143.
PubMed
14) Qureshi M, et al. The natural history of ALS is changing : Improved survival. Amyotroph Lateral Scler 2009 ; 10 : 324-331.
PubMed
15) Traynor BJ, et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria : A population-based study. Arch Neurol 2000 ; 57 : 1171-1176.
 
16) Shoesmith CL, et al. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry 2007 ; 78 : 629-631.
PubMed
17) Forbes RB, et al ; Scottish ALS / MND Register. The epidemiology of amyotrophic lateral sclerosis (ALS / MND) in people aged 80 or over. Age Ageing 2004 ; 33 : 131-134.
 
18) Paganoni S, et al. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 2011 ; 44 : 20-24.
 
19) Olney RK, et al. The effects of executive and behavioral dysfunction on the course of ALS. Neurology 2005 ; 65 : 1774-1777.
PubMed
20) Fujimura-Kiyono C, et al. Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011 ; 82 : 1244-1249.
PubMed
21) Turner MR, et al. Pattern of spread and prognosis in lower limb-onset ALS. Amyotroph Lateral Scler 2010 ; 11 : 369-373.
PubMed
22) Kimura F, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006 ; 66 : 265-267.
 
23) Kollewe K, et al. ALSFRS-R score and its ratio : A useful predictor for ALSprogression. J Neurol Sci 2008 ; 275 : 69-73.
PubMed
24) Czaplinski A, et al. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 2006 ; 77 : 390-392.
 
P.40 掲載の参考文献
1) Kimura J. Electrodiagnosis in Disease of Nerve and Muscle : Principles and Practice. New York : Oxford University Press ; 2001.
 
2) Nobile-Orazio E, et al. Multifocal motor neuropathy : Current concepts and controversies. Muscle Nerve 2005 ; 31 : 663-680.
PubMed
3) Nodera H, et al. Activity-dependent conduction block in multifocal motor neuropathy : Magnetic fatigue test. Neurology 2006 ; 67 : 280-287.
PubMed
4) Mitsumoto H, et al. Transcranial magnetic stimulation for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Suppl Clin Neurophysiol 2006 ; 59 : 327-332.
PubMed
5) Rosler KM, et al. Quantification of upper motor neuron loss in amyotrophic lateral sclerosis. Clin Neurophysiol 2000 ; 111 : 2208-2218.
PubMed
6) Killian JM, et al. Decremental motor responses to repetitive nerve stimulation in ALS. Muscle Nerve 1994 ; 17 : 747-754.
PubMed
7) Lambert E. Electromyography in amyotrophic lateral sclerosis. In : Kurland LT, et al (editors). Motor Neuron Diseases. New York : Grune & Stratton ; 1969, pp.135-153.
 
8) Brooks BR, et al. El Escorial revisited : Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000 ; 1 : 293-299.
 
9) de Carvalho M, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008 ; 119 : 497-503.
PubMed
10) Bromberg MB, Brownell AA. Motor unit number estimation in the assessment of performance and function in motor neuron disease. Phys Med Rehabil Clin N Am 2008 ; 19 : 509-532, ix.
 
11) Bostock H, et al. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998 ; 21 : 137-158.
 
12) Rutkove SB. Electrical impedance myography : Background, current state, and future directions. Muscle Nerve 2009 ; 40 : 936-946.
PubMed
P.47 掲載の参考文献
1) Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009 ; 65 (Suppl 1) : S3-9.
 
2) Bostock H, et al. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998 ; 21 : 137-158.
 
3) Layzer RB. The origin of muscle fasciculations and cramps. Muscle Nerve 1994 ; 17 : 1243-1249.
PubMed
4) Newsom-Davis J. Autoimmune neuromyotonia (Isaacs'syndrome) : An antibodymediated potassium channelopathy. Ann N Y Acad Sci 1997 ; 835 : 111-119.
PubMed
5) Kanai K, et al. Muscle cramp in Machado-Joseph disease : Altered motor axonal excitability properties and mexiletine treatment. Brain 2003 ; 126 : 965-973.
PubMed
6) Bostock H, Rothwell JC. Latent addition in motor and sensory fibres of human peripheral nerve. J Physiol 1997 ; 498 : 277-294.
PubMed
7) 桑原聡, 金井数明. ALSの軸索イオンチャネル障害. BRAIN and NERVE 2007 ; 59 : 1109-1115.
 
8) Mogyoros I, et al. Strength-duration properties of sensory and motor axons in amyotrophic lateral sclerosis. Brain 1998 ; 121 : 851-859.
PubMed
9) Priori A, et al. Distinctive abnormalities of motor axonal strength-duration properties in multifocal motor neuropathy and in motor neurone disease. Brain 2002 ; 125 : 2481-2490.
PubMed
10) Kanai K, et al. Altered axonal excitability properties in amyotrophic lateral sclerosis : Impaired potassium channel function related to disease stage. Brain 2006 ; 129 : 953-962.
PubMed
11) Vucic S, Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol 2006 ; 117 : 1458-1466.
PubMed
12) Tamura N, et al. Increased nodal persistent Na+ currents in human neuropathy and motor neuron disease estimated by latent addition. Clin Neurophysiol 2006 ; 117 : 2451-2458.
PubMed
13) Devor M, et al. Na+ channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation. J Neurosci 1993 ; 13 : 1976-1992.
PubMed
14) Bostock H, et al. Axonal ion channel dysfunction in amyotrophic lateral sclerosis. Brain 1995 ; 118 : 217-225.
PubMed
15) Eisen A, et al. Amyotrophic lateral sclerosis (ALS) : A phylogenetic disease of the corticomotoneuron? Muscle Nerve 1992 ; 15 : 219-224.
 
16) Kuwabara S, et al. Dissociated small hand muscle involvement in amyotrophic lateral sclerosis detected by motor unit number estimates. Muscle Nerve 1999 ; 22 : 870-873.
PubMed
17) Wilbourn AJ. The "split hand syndrome". Muscle Nerve 2000 ; 23 : 138.
PubMed
18) Kuwabara S, et al. Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis : Frequency, extent, and specificity. Muscle Nerve 2008 ; 37 : 426-430.
PubMed
19) Eisen A, Kuwabara S. The split hand syndrome in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2012 ; 83 : 399-403.
PubMed
20) Bae JS, et al. Differences in excitability properties of FDI and ADM motor axons. Muscle Nerve 2009 ; 39 : 350-354.
PubMed
21) Kanai K, et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2012 ; 83 : 734-738.
PubMed
P.56 掲載の参考文献
1) Brooks BR, et al ; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited : Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000 ; 1 : 293-299.
 
2) Hecht MJ, et al. MRI-FLAIR images of the head show corticospinal tract alterations in ALS patients more frequently than T2-, T1- and proton-density-weighted images. J Neurol Sci 2001 ; 186 : 37-44.
PubMed
3) Oba H, et al. Amyotrophic lateral sclerosis : T2 shortening in motor cortex at MR imaging. Radiology 1993 ; 189 : 843-846.
PubMed
4) Kwan JY, et al. Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS : Correlating 7 tesla MRI and pathology. PLoS One 2012 ; 7 : e35241.
PubMed
5) Filippi M, et al. EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases. Eur J Neurol 2010 ; 17 : 526-e20.
PubMed
6) Mori H, et al. Symmetric temporal abnormalities on MR imaging in amyotrophic lateral sclerosis with dementia. AJNR Am J Neuroradiol 2007 ; 28 : 1511-1516.
PubMed
7) Kassubek J, et al. Neuroimaging of motor neuron diseases. Ther Adv Neurol Disord 2012 ; 5 : 119-127.
PubMed
8) Kassubek J, et al. Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel-based morphometry of 3-D MRI. Amyotroph Lateral Scler Other Motor Neuron Disord 2005 ; 6 : 213-220.
PubMed
9) Chang JL, et al. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. Neurology 2005 ; 65 : 75-80.
PubMed
10) Ellis CM, et al. Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology 1999 ; 53 : 1051-1058.
PubMed
11) Iwata NK, et al. Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation. Neurology 2008 ; 70 : 528-532.
PubMed
12) Iwata NK, et al. White matter alterations differ in primary lateral sclerosis and amyotrophic lateral sclerosis. Brain 2011 ; 134 : 2642-2655.
PubMed
13) Sato K, et al. Diffusion tensor tract-specific analysis of the uncinate fasciculus in patients with amyotrophic lateral sclerosis. Neuroradiology 2010 ; 52 : 729-733.
PubMed
14) Aoki S, et al. Quantitative evaluation of the pyramidal tract segmented by diffusion tensor tractography : Feasibility study in patients with amyotrophic lateral sclerosis. Radiat Med 2005 ; 23 : 195-199.
PubMed
15) Ellis CM, et al. A proton magnetic resonance spectroscopic study in ALS : Correlation with clinical findings. Neurology 1998 ; 51 : 1104-1109.
PubMed
16) Schoenfeld MA, et al. Functional motor compensation in amyotrophic lateral sclerosis. J Neurol 2005 ; 252 : 944-952.
PubMed
17) Mohammadi B, et al. Changes of resting state brain networks in amyotrophic lateral sclerosis. Exp Neurol 2009 ; 217 : 147-153.
PubMed
18) Tanaka M, et al. Cerebral blood flow and oxygen metabolism in patients with progressive dementia and amyotrophic lateral sclerosis. Neurol Res 2003 ; 25 : 351-356.
PubMed
P.63 掲載の参考文献
1) Ichikawa H, et al. Writing errors and anosognosia in amyotrophic lateral sclerosis with dementia. Behav Neurol 2008 ; 19 : 107-116.
 
2) 市川博雄. 筋萎縮性側索硬化症における書字障害と孤立性失書. 高次脳機能研究 2009 ; 29 : 231-238.
 
3) Neary D, et al. Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry 1990 ; 53 : 23-32.
PubMed
4) Neary D, et al. Frontotemporal lobar degeneration : A consensus on clinical diagnostic criteria. Neurology 1998 ; 51 : 1546-1554.
PubMed
5) Geser F, et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009 ; 66 : 180-189.
PubMed
6) Giordana MT, et al. Dementia and cognitive impairment in amyotrophic lateral sclerosis : A review. Neurol Sci 2011 ; 32 : 9-16.
PubMed
7) Ichikawa H, et al. Writing error may be a predictive sign for impending brain atrophy progression in amyotrophic lateral sclerosis : A preliminary study using X-ray computed tomography. Eur Neurol 2011 ; 65 : 346-351.
PubMed
8) 池田研二. 前方型痴呆 (anterior type dementia) -その概念と病理. 老年精神医学 2004 ; 15 : 1302-1311.
Medical*Online
9) 池田学. 前頭側頭型認知症の症候学. 臨床神経学 2008 ; 48 : 1002-1004.
 
10) 市川博雄. 前頭側頭葉変性症. 河村満 (編), アクチュアル 脳・神経疾患の臨床, 認知症-神経心理学的アプローチ. 東京 : 中山書店 ; 2012, pp.222-229.
 
11) Deckel AW, Morrison D. Evidence of a neurologically based "denial of illness" in patients with Huntington's disease. Arch Clin Neuropsychol 1996 ; 11 : 295-302.
PubMed
12) Ichikawa H, et al. Amyotrophic lateral sclerosis and language dysfunction : Kana, kanji and a prescient report in Japanese by Watanabe (1893). Eur Neurol 2011 ; 65 : 144-149.
 
13) Ringholz GM, et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005 ; 65 : 586-590.
PubMed
14) 寺田達弘ほか. 筋萎縮性側索硬化症におけるFrontal Assessment Batteryによる前頭葉機能評価. 臨床神経学 2010 ; 50 : 379-384.
 
15) Ichikawa H, et al. Kana versus kanji in amyotrophic lateral sclerosis : A clinicoradiological study of writing errors. Eur Neurol 2010 ; 64 : 148-155.
PubMed
16) Abrahams S, et al. Word retrieval in amyotrophic lateral sclerosis : A functional magnetic resonance imaging study. Brain 2004 ; 127 : 1507-1517.
PubMed
・ Strong MJ (editor). Amyotrophic Lateral Sclerosis and the Frontotemporal Dementias. Oxford : Oxford University Press ; 2012.
 
・ Kertesz A. The Banana Lady and Other Stories of Curious Behavior and Speech. Bloomington : Trafford Publishing ; 20060/河村満 (監訳). バナナ・レディ-前頭側頭型認知症をめぐる19のエピソード. 東京 : 医学書院 ; 2010.
 

III. ALSと関連運動ニューロン疾患

P.74 掲載の参考文献
1) DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011 ; 72 : 245-256.
PubMed
2) Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011 ; 72 : 257-268.
PubMed
3) Konno T, et al. Japanese amyotrophic lateral sclerosis patients with GGGGCC hexanucleotide repeat expansion in C9ORF72. J Neurol Neurosurg Psychiatry doi : 10.1136/jnnp-2012-302272
 
4) 熱田直樹, 祖父江元. 孤発性ALSの疫学. Clin Neurosci 2008 ; 26 : 266-267.
 
5) Logroscino G, et al. Descriptive epidemiology of amyotrophic lateral sclerosis : New evidence and unsolved issues. J Neurol Neurosurg Psychiatry 2008 ; 79 : 6-11.
PubMed
6) McKee AC, et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010 ; 69 : 918-929.
PubMed
7) Turner MR, et al. Mills' and other isolated upper motor neurone syndromes : In vivo study with 11C - (R) -PK11195 PET. J Neurol Neurosurg Psychiatry 2005 ; 76 : 871-874.
 
8) 佐々木彰一. ALSの病型-臨床と病理. BRAIN and NERVE 2007 ; 59 : 1013-1021.
 
9) Gonatas NK, et al. Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis. Am J Pathol 1992 ; 140 : 731-737.
 
10) Migheli A, et al. A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol 1994 ; 53 : 606-616.
 
11) Yamazaki M, et al. Is motoneuronal cell death in amyotrophic lateral sclerosis apoptosis? Neuropathology 2005 ; 25 : 381-387.
PubMed
12) Nakano I, et al. On the possibility of autolysosomal processing of skein-like inclusions. Electron microscopic observation in a case of amyotrophic lateral sclerosis. J Neurol Sci 1993 ; 120 : 54-59.
 
13) Nakano I. Frontotemporal dementia with motor neuron disease (amyotrophic lateral sclerosis with dementia). Neuropathology 2000 ; 20 : 68-75.
PubMed
14) Zhang H, et al. TDP-43-immunoreactive neuronal and glial inclusions in the neostriatum in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol 2008 ; 115 : 115-122.
PubMed
15) Cushman M, et al. Prion-like disorders : Blurring the divide between transmissibility and infectivity. J Cell Sci 2010 ; 123 : 1191-1201.
PubMed
16) Fujimura-Kiyono C, et al. Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011 ; 82 : 1244-1249.
PubMed
P.81 掲載の参考文献
1) Okamoto K, et al. Bunina bodies in amyotrophic lateral sclerosis. Neuropathology 2008 ; 28 : 109-115.
PubMed
2) Lowe J, et al. A filamentous inclusion body within anterior horn neurones in motor neurone disease defined by immunocytochemical localisation of ubiquitin. Neurosci Lett 1988 ; 94 : 203-210.
 
3) Yuasa R. Amyotrophic lateral sclerosis with organic dementia. Report a case. Clin Neurol 1964 ; 4 : 529-534. (In Japanese)
 
4) Mitsuyama Y, Takamiya S. Presenile dementia with motor neuron disease in Japan. A new entity? Arch Neurol 1979 ; 36 : 592-593.
PubMed
5) Piao YS, et al. Neuropathology with clinical correlations of sporadic amyotrophic lateral sclerosis : 102 autopsy cases examined between 1962 and 2000. Brain Pathol 2003 ; 13 (1) : 10-22.
PubMed
6) Cairns NJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration : Consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007 ; 114 : 5-22.
 
7) Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006 ; 314 (5796) : 130-133.
PubMed
8) Kwiatkowski TJ Jr, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009 ; 323 : 1205-1208.
PubMed
9) Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009 ; 323 : 1208-1211.
PubMed
10) Mackenzie IR, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration : An update. Acta Neuropathol 2010 ; 119 : 1-4.
PubMed
11) Nishihira Y, et al. Sporadic amyotrophic lateral sclerosis : Two pathological patterns shown by analysis of distribution of TDP-43-immunoreactive neuronal and glial cytoplasmic inclusions. Acta Neuropathol 2008 ; 116 : 169-182.
PubMed
12) Mackenzie IR, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011 ; 122 : 111-113.
PubMed
13) Sieben A, et al. The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol 2012 ; 124 : 353-372.
PubMed
・ Gray F, et al (editors). Escourolle & Poirier, Manual of Basic Neuropathology. 4th edition. Philadelphia : Butterworth-Heinemann ; 2004.
 
・ Love S, et al (editors). Greenfield's Neuropathology. 8th edition. London : Hodder Arnold ; 2008.
 
・ Dickson DW, Weller RO (editors). Neurodegeneration : The Molecular Pathology of Dementia and Movement Disorders. 2nd edition. Oxford : Blackwell Publishing Ltd ; 2011.
 
P.93 掲載の参考文献
1) Nishihira Y, Tan CF, Onodera O, et al. Sporadic amyotrophic lateral sclerosis : Two pathological patterns shown by analysis of distribution of TDP-43-immunoreactive neuronal and glial cytoplasmic inclusions. Acta Neuropathol 2008 ; 116 : 169-182.
PubMed
2) Mitsuyama Y. Presenile dementia with motor neuron disease in Japan : Clinicopathological review of 26 cases. J Neurol Neurosurg Psychiatry 1984 ; 47 : 953-959.
 
3) Miki Y, Mori F, Nunomura J, et al. Sporadic amyotrophic lateral sclerosis with pallido-nigro-luysian degeneration : A TDP-43 immunohistochemical study. Neuropathology 2010 ; 30 : 149-153.
PubMed
4) Okamoto K, Hirai S, Yamazaki T, Sun XY, Nakazato Y. New ubiquitin-positive intraneuronal inclusions in the extra-motor cortices in patients with amyotrophic lateral sclerosis. Neurosci Lett 1991 ; 129 : 233-236.
PubMed
5) Tsuji H, Arai T, Kametani F, et al. Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain 2012 ; 135 : 3380-3391.
PubMed
P.99 掲載の参考文献
1) 高橋祐二ほか. わが国の遺伝性ALS-Overview. 神経内科 2012 ; 76 : 459-466.
 
2) 二瓶義廣ほか. 家族性ALSと孤発性ALS発症関連遺伝子オーバービュー. Clinical Neuroscience 2011 ; 29 : 1015-1018.
 
3) 今野卓哉ほか. C9ORF72遺伝子の非翻訳領域におけるGGGGCCリピート異常伸長を伴うFTD/ALS. Dementia Japan 2012 ; 26 : 206-215.
 
P.103 掲載の参考文献
1) Eisen AA. Primary lateral sclerosis. In : Eisen AA, Shaw PJ (editors). Motor Neuron Disorders and Related Diseases. Handbook of Clinical Neurology, Vol 82. Edinburgh : Elsevier ; 2007, pp.315-325.
 
2) Swash M, et al. What is primary lateral sclerosis? J Neurol Sci 1999 ; 170 : 5-10.
PubMed
3) Le Forestier N, et al. Does primary lateral sclerosis exit? A study of 20 patients and review of the literature. Brain 2001 ; 124 : 1989-1999.
 
4) Singer MA, et al. Primary lateral sclerosis. Muscle Nerve 2007 ; 35 : 291-302.
PubMed
5) 中野今治, 森田光哉. 原発性側索硬化症. 厚生労働科学研究費補助金難治性疾患克服研究事業 神経変性疾患に関する調査研究班 (主任研究者 葛原茂樹), 2007年度研究報告書. 2008, pp.17-20.
 
6) Pringle CE, et al. Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria. Brain 1992 ; 115 : 495-520.
PubMed
7) Brugman F, et al. New diagnostic criteria for primary lateral sclerosis : A prospective validation study. 20th International Symposium on ALS / MND, Berlin, 2009.
 
8) Gordon PH, et al. The natural history of primary lateral sclerosis. Neurology 2006 ; 66 : 647-653.
PubMed
9) Tan CF, et al. Primary lateral sclerosis : A rare upper-motor-predominant form of amyotrophic lateral sclerosis often accompanied by frontotemporal lobar degeneration with ubiquitinated neuronal inclusions? Report of an autopsy case and a review of the literature. Acta Neuropathol 2003 ; 105 : 615-620.
 
10) Tsuchiya K, et al. Sporadic amyotrophic lateral sclerosis resembling primary lateral sclerosis : Report of an autopsy case and a review of the literature. Neuropathology 1999 ; 19 : 71-76.
 
11) 小阪崇幸ほか. 原発性側索硬化症 : その神経病理と生化学的所見について. 厚生労働省科学研究費補助金難治性疾患克服研究事業 筋萎縮性側索硬化症の分子病態解明と新規治療法創出に関する研究班 (研究代表者 長谷川成人), 平成24年度班会議抄録. 2012.
 
12) Ikeda K, et al. Morphometrical reappraisal of motor neuron system of Pick's disease and amyotrophic lateral sclerosis with dementia. Acta Neuropathol 2002 ; 104 : 21-28.
PubMed
13) McDermott CJ, Shaw AJ. Hereditary spastic paraperesis. In : Eisen AA, Shaw PJ (editors). Motor Neuron Disorders and Related Diseases. Handbook of Clinical Neurology, Vol 82. Edinburgh : Elsevier ; 2007, pp.327-352.
 
14) 瀧山嘉久. 遺伝性痙性対麻痺. 山梨医科学誌 2009 ; 24 : 1-12.
 
15) Brugman F, et al. Primary lateral sclerosis as a phenotypic manifestation of familiar ALS. Neurology 2005 ; 64 : 1778-1779.
 
P.108 掲載の参考文献
1) Brownell B, et al. The central nervous system in motor neurone disease. J Neurol Neurosurg Psychiatry 1970 ; 33 : 338-357.
PubMed
2) Ince PG, et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 2003 ; 60 : 1252-1258.
PubMed
3) Geser F, et al. Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. Acta Neuropathol 2011 ; 121 : 509-517.
 
4) Nishihira Y, et al. Sporadic amyotrophic lateral sclerosis of long duration is associated with relatively mild TDP-43 pathology. Acta Neuropathol 2009 ; 117 : 45-53.
PubMed
5) Kim WK, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 2009 ; 73 : 1686-1692.
PubMed
6) Traynor BJ, et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria : A population-based study. Arch Neurol 2000 ; 57 : 1171-1176.
 
7) Wijesekera LC, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 2009 ; 72 : 1087-1094.
PubMed
8) Katz JS, et al. Brachial amyotrophic diplegia : A slowly progressive motor neuron disorder. Neurology 1999 ; 53 : 1071-1076.
 
9) Chio A, et al ; PARALS study group. Phenotypic heterogeneity of amyotrophic lateral sclerosis : A population based study. J Neurol Neurosurg Psychiatry 2011 ; 82 : 740-746.
 
P.115 掲載の参考文献
1) 高橋昭. 日本の神経学の黎明期. 日内会誌 2002 ; 91 : 2241-2244.
 
2) Kennedy WR, et al. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968 ; 18 : 671-680.
PubMed
3) La Spada AR, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991 ; 352 : 77-79.
 
4) Tanaka F, et al. Founder effect in spinal and bulbar muscular atrophy (SBMA). Hum Mol Genet 1996 ; 5 : 1253-1257.
PubMed
5) Doyu M, et al. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 1992 ; 32 : 707-710.
PubMed
6) Katsuno M, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002 ; 35 : 843-854.
 
7) Atsuta N, et al. Natural history of spinal and bulbar muscular atrophy (SBMA) : A study of 223 Japanese patients. Brain 2006 ; 129 : 1446-1455.
PubMed
8) Suzuki K, et al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain 2008 ; 131 : 229-239.
PubMed
9) Hashizume A, et al. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain 2012 ; 135 : 2838-2848.
PubMed
10) Katsuno M, et al. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Exp Neurol 2006 ; 200 : 8-18.
PubMed
11) Sobue G, et al. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 1989 ; 112 : 209-232.
PubMed
12) Adachi H, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 2005 ; 128 : 659-670.
PubMed
13) Banno H, et al. Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin : A pathogenic marker. Ann Neurol 2006 ; 59 : 520-526.
PubMed
14) Katsuno M, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003 ; 9 : 768-773.
 
15) Banno H, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 2009 ; 65 : 140-150.
PubMed
16) Katsuno M, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study) : A multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010 ; 9 : 875-884.
PubMed
・ La Spada AR, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991 ; 352 : 77-79.
 
P.123 掲載の参考文献
1) Munsat TL, Workshop report. International SMA Collaboration. Neuromusc Disord 1991 ; 1 : 81.
 
2) 斎藤加代子ほか. 脊髄性筋萎縮症の臨床の分析と遺伝子解析. 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 神経変性疾患に関する調査研究班 平成21年度研究報告書. 2010, pp.104-107.
 
3) Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 1995 ; 52 : 518-523.
PubMed
4) Zerres K, et al. Genetic basis of adult-onset spinal muscular atrophy. Lancet 1995 ; 346 : 1162.
PubMed
5) Brahe C, et al. Genetic homogeneity between childhood-onset and adult-onset autosomal recessive spinal muscular atrophy. Lancet 1995 ; 346 : 741-742.
PubMed
6) Pearn JH, et al. A clinical and genetic study of spinal muscular atrophy of adult onset : The autosomal recessive form as a discrete disease entity. Brain 1978 ; 101 : 591-606.
PubMed
7) Lefebvre S, et al. Identification and characterization of a spinal muscular atrophy determining gene. Cell 1995 ; 80 : 155-165.
PubMed
8) Roy N, et al. The gene for neuronal apoptosis inhibitory protein is partially deleted individuals with spinal muscular atrophy. Cell 1995 ; 80 : 167-178.
PubMed
9) Blauw HM, et al. SMN1 gene duplications are associated with sporadic ALS. Neurology 2012 ; 78 : 776-780.
PubMed
10) 斎藤加代子ほか. 脊髄性筋萎縮症の臨床と分子遺伝学. 東京女子医科大学雑誌 2000 ; 70 (臨増 1) : E2-E9.
 
11) Ito M, et al. Phenotype-Genotype correlation in Japanese spinal muscular atrophy patients : Analysis of DNA and mRNA of the SMN gene. J Tokyo Wom Med Univ 2004 ; 74 : 167-178.
 
12) Wirth B, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet 2006 ; 119 : 422-428.
PubMed
13) Rudnik-Schoneborn S, et al. Clinical spectrum and diagnostic criteria of infantile spinal muscular atrophy : Further delineation on the basis of SMN gene deletion findings. Neuropediatrics 1996 ; 27 : 8-15.
PubMed
14) Hua Y, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011 ; 478 : 123-126.
PubMed
P.133 掲載の参考文献
1) Garruto RM, Yanagihara R. Amyotrophic lateral sclerosis in the Mariana Islands. In : De Jong JMBV (editor). Handbook of Clinical Neurology. vol.15 (59). Diseases of the Motor System. Amsterdam : Elsevier Science Publishers ; 1991, pp.253-271.
 
2) Hirano A, et al. Parkinsonism-dementia complex, an endemic disease on the island of Guam : II. Pathological features. Brain 1961 ; 84 : 662-679.
PubMed
3) 葛原樹. 牟婁病-紀伊ALS・パーキンソン認知症複合. BRAIN and NERVE 2011 ; 63 : 119-129.
 
4) Yase Y, et al. Japanese contribution to neuropathology : Kii ALS dementia. Neuropathology 2001 ; 21 : 105-109.
 
5) 吉田宗平. シンポジウム I : 筋萎縮性側索硬化症の成因をめぐって-1. ALS 多発地における環境要因とアルミニウムのニューロン変性への関与について. 臨床神経 1991 ; 31 : 1310-1312.
 
6) Kuzuhara S, et al. Familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii peninsula of Japan : Clinical and neuropathological study and tau analysis. Ann Neurol 2001 ; 49 : 501-511.
PubMed
7) Gajdusek, DC, Salazar AM. Amyotrophic lateral sclerosis an parkinsonian syndromes in high incidence among the Auyu and Jakai people of West New Guinea. Neurology 1982 ; 32 : 107-126.
PubMed
8) 奥宮清人ほか. 西ニューギニア地域 (インドネシア・パプア州) の神経変性疾患の実態-2001～02年, 2006～07年のフィールドワークより. 臨床神経 2007 ; 47 : 977-978.
 
9) 小久保康昌, 葛原樹. 紀伊半島多発地域の筋萎縮性側索硬化症とパーキンソン痴呆複合の臨床神経学的および神経病理学的検討. 臨床神経 2001 ; 41 : 769-774.
 
10) Hasegawa M, et al. TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 2007 ; 130 : 1386-1394.
PubMed
11) 葛原樹. 紀伊半島ALS/PDCとTDP-43. 神経内科 2008 ; 68 : 565-570.
 
12) Mimuro M, et al. Similar topographical distribution of neurofibrillary tangles in amyotrophic lateral sclerosis and parkinsonism-dementia complex in people living in the Kii peninsula of Japan suggests a single tauopathy. Acta Neuropathol 2007 ; 113 : 653-658.
PubMed
13) Garruto RM, Yanagihara R. Contributions of isolated Pacific populations to understanding neurodegenerative diseases. Folia Neuropathol 2009 ; 47 : 149-170.
PubMed
14) Yase Y. The pathogenesis of amyotrophic lateral sclerosis. Lancet 1972 ; 2 : 292-296.
PubMed
15) Spencer PS, et al. Cycad use and motor neurone disease in Kii peninsula of Japan. Lancet 1987 ; 2 : 1462-1463.
PubMed
16) Ishiura H, et al. C9orf72 repeat expansion in amyotrophic lateral sclerosis in the Kii peninsula of Japan. Arch Neurol 2012 ; 69 : 1154-1158.
PubMed
17) Tomiyama H, et al. Mutation analyses in amyotrophic latetal sclerosis/parkinsonismdementia complex of Kii peninsula, Japan. Mov Disord 2008 ; 23 : 2344-2348.
 
18) Hara K, et al. TRPM7 is not associated with amyotrophic lateral sclerosisparkinsonism dementia complex in the Kii peninsula of Japan. Am J Med Genet B Neuropsychiatr Genet 2010 ; 153B : 310-313.
 
19) Galasko D, et al. Prevalence of dementia in Chamorros on Guam : Relationship to age, gender, education, and APOE. Neurology 2007 ; 68 : 1772-1781.
PubMed
・ Shiraki H, Yase Y. Amyotrophic lateral sclerosis in Japan. In : Vinken PJ, et al (editors). Handbook of Clinical Neurology. vol.22. System Disorders and Atrophies. Part II. Amsterdam : North Holland Publishing Company ; 1975, pp.353-419.
 
・ Garruto RM. Lessons from the study of natural experiments of hyperendemic foci of neurodegeneration. In : Strong MJ (editor). Amyotrophic Lateral Sclerosis and the Frontotemporal Dementias. Oxford : Oxford University Press ; 2012, pp.1-26.
 
・ Kuzuhara S, Kokubo Y. Amyotrophic lateral sclerosis-parkinsonism-dementia complex in the Kii peninsula of Japan (Muro disease) : A review on recent research and new concept. ditto, pp.39-54.
 
P.139 掲載の参考文献
1) 平山惠造. 神経症候学 改訂第二版. 東京 : 文光堂 ; 2010, pp.281-288.
 
2) 平山惠造. 若年性一側上肢筋萎縮症 (平山病) - 発見からの半世紀. BRAIN and NERVE 2008 ; 60 : 17-29.
 
3) Hirayama K. Non-progressive juvenile spinal muscular atrophy of distal upper limb (Hirayama disease). de Jong JMBV (editor). Diseases of the Motor System. Handbook of Clinical Neurology, Vol 59/revised series 15. Amsterdam : Elsevier, 1991, pp.107-120.
 
4) 得丸幸夫. 平山病の予後と治療. 神経内科 1998 ; 48 : 349-353.
 
5) 得丸幸夫. 若年性一側上肢筋萎縮症 (平山病)の神経放射線学的所見. 脊椎脊髄ジャーナル 1992 ; 5 : 99-108.
 
6) 得丸幸夫. 若年性一側上肢筋萎縮症 (平山病). 脊椎脊髄ジャーナル 2001 ; 14 : 508-511.
 
7) 桑原聡ほか. 平山病 (若年性一側上肢筋萎縮症)の診断と病態. 脊椎脊髄ジャーナル 2002 ; 15 : 527-530.
 
8) 得丸幸夫. 平山病の治療と将来展望. 神経内科 2006 ; 65 : 243-248.
 
9) 得丸幸夫, 平山惠造. 若年性一側上肢筋萎縮症 (平山病)の頸椎カラー療法- 38例での治療成績. 臨床神経学 2001 ; 41 : 173-178.
 
10) 平山惠造ほか. 若年性一側上肢筋萎縮症 (平山病) 全国調査. 若年性一側上肢筋萎縮症 (平山病) 全国調査研究グループ ; 2000.
 
P.147 掲載の参考文献
1) Manabe Y, et al. A case of spinocerebellar ataxia accompanied by severe involvement of the motor neuron system. Neurol Res 2000 ; 22 : 567-570.
PubMed
2) Ohta Y, et al. Two cases of spinocerebellar ataxia accompanied by involvement of the skeletal motor neuron system and bulbar palsy. Intern Med 2007 ; 46 : 751-755.
PubMed
3) Abe K, et al. Cognitive and affective impairments of a novel SCA/MND crossroad mutation Asidan. Eur J Neurol 2012 ; 19 : 1070-1078.
 
4) Ikeda Y, et al. Clinical features of SCA36 : A novel spinocerebellar ataxia with motor neuron involvement (Asidan). Neurology 2012 ; 79 : 333-341.
PubMed
5) Kameya T, et al. Analysis of spinocerebellar ataxia type 1 (SCA1) -related CAG trinucleotide expansion in Japan. Neurology 1995 ; 45 : 1587-1594.
PubMed
6) Watanabe M, et al. Analysis of CAG trinucleotide expansion associated with Machado-Joseph disease. J Neurol Sci 1996 ; 136 : 101-107.
PubMed
7) Goldfarb LG, et al. Unstable triplet repeat and phenotypic variability of spinocerebellar ataxia type 1. Ann Neurol 1996 ; 39 : 500-506.
PubMed
8) Morimoto N, et al. Assessment of swallowing in motor neuron disease and Asidan/SCA36 patients with new methods. J Neurol Sci 2013 ; 324 : 149-155.
PubMed
9) Ikeda Y, et al. Acoustic impairment is a distinguishable clinical feature of Asidan/SCA36. J Neurol Sci 2013 ; 324 : 109-112.
PubMed
10) Ikeda Y, et al. Comparisons of acoustic function in SCA31 and other forms of ataxias. Neurol Res 2011 ; 33 : 427-432.
PubMed
11) Kobayashi H, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am J Hum Genet 2011 ; 89 : 121-130.
PubMed
12) Vercelletto M, et al. Frontal type dementia preceding amyotrophic lateral sclerosis : A neuropsychological and SPECT study of five clinical cases. Eur J Neurol 1999 ; 6 : 295-299.
PubMed
13) Ishikawa T, et al. Constant blood flow reduction in premotor frontal lobe regions in ALS with dementia-A SPECT study with 3D-SSP. Acta Neurol Scand 2007 ; 116 : 340-344.
PubMed
14) Abrahams S, et al. A positron emission tomography study of frontal lobe function (verbal fluency) in amyotrophic lateral sclerosis. J Neurol Sci 1995 ; 129 Suppl : 44-46.
 

IV. ALSの病態関連遺伝子と遺伝子変異

P.156 掲載の参考文献
1) Byrne S, et al. Rate of familial amyotrophic lateral sclerosis : A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2011 ; 82 : 623-627.
PubMed
2) Rosen DR, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993 ; 362 : 59-62.
PubMed
3) Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994 ; 264 : 1772-1775.
PubMed
4) Wu CH, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 2012 ; 488 : 499-503.
PubMed
5) Iida A, et al. A functional variant in ZNF512B is associated with susceptibility to amyotrophic lateral sclerosis in Japanese. Hum Mol Genet 2011 ; 20 : 3684-3692.
PubMed
6) 渡辺保裕ほか. ALS1 (SOD1). 神経内科 2012 ; 76 : 467-471.
 
7) Boillee S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006 ; 312 : 1389-1392.
PubMed
8) Yamanaka K, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008 ; 11 : 251-253.
PubMed
9) Akimoto C, et al. High-Resolution Melting (HRM) Analysis of the Cu / Zn superoxide dismutase (SOD1) gene in Japanese sporadic amyotrophic lateral sclerosis (SALS) patients. Neurol Res Int 2011 : 165415.
PubMed
10) Aoki M, et al. Mild ALS in Japan associated with novel SOD mutation. Nat Genet 1993 ; 5 : 323-324.
PubMed
11) Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis : What do we really know? Nat Rev Neurol 2011 ; 7 : 603-615.
PubMed
12) Al-Chalabi A, et al. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol 2012 ; 124 : 339-352.
PubMed
P.164 掲載の参考文献
1) 白川健太郎, 宮嶋裕明. ALS2 (alsin). 神経内科 2012 ; 76 (5) : 472-476.
 
2) Ben Hamida M, et al. Hereditary motor system diseases (chronic juvenile amyotrophic lateral sclerosis). Conditions combining a bilateral pyramidal syndrome with limb and bulbar amyotrophy. Brain 1990 ; 113 (Pt2) : 347-363.
 
3) Hentati A, et al. Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. Nat Genet 1994 ; 7 (3) : 425-428.
PubMed
4) Hadano S, et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 2001 ; 29 (2) : 166-173.
PubMed
5) Yang Y, et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 2001 ; 29 (2) : 160-165.
 
6) Hadano S, et al. Molecular and cellular function of ALS2/alsin : Implication of membrane dynamics in neuronal development and degeneration. Neurochem Int 2007 ; 51 (2-4) : 74-84.
 
7) Sztriha L, et al. First case of compound heterozygosity in ALS2 gene in infantile-onset ascending spastic paralysis with bulbar involvement. Clin Genet 2008 ; 73 (6) : 591-593.
PubMed
8) Herzfeld T, et al. Maternal uniparentalheterodisomy with partial isodisomy of a chromosome 2 carrying a splice acceptor site mutation (IVS9-2A > T) in ALS2 causes infantile-onset ascending spastic paralysis (IAHSP). Neurogenetics 2009 10 (1) : 59-64.
PubMed
9) Shirakawa K, et al. Novel compound heterozygous ALS2 mutations cause juvenile amyotrophic lateral sclerosis in Japan. Neurology 2009 ; 73 (24) : 2124-2126.
PubMed
10) Otomo A, et al. Defective relocalization of ALS2/alsin missense mutants to Rac1-induced macropinosomes accounts for loss of their cellular function and leads to disturbed amphisome formation. FEBS Lett 2011 ; 585 (5) : 730-736.
PubMed
11) Kunita R, et al. The Rab5 activator ALS2/alsin acts as a novel Rac1 effector through Rac1-activated endocytosis. J Biol Chem ; 2007 : 282 (22) : 16599-16611.
PubMed
12) Cai H, et al. ALS2 / alsin knockout mice and motor neuron diseases. Neurodegener Dis 2008 ; 5 (6) : 359-366.
PubMed
13) Hadano S, et al. Loss of ALS2 / Alsin exacerbates motor dysfunction in a SOD1H46R expressing mouse ALS model by disturbing endolysosomal trafficking. PLoS One 2010 ; 5 (3) : e9805.
 
P.171 掲載の参考文献
1) Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006 ; 351 (3) : 602-611.
PubMed
2) Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006 ; 314 (5796) : 130-133.
PubMed
3) Chen-Plotkin AS, et al. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 2010 ; 6 (4) : 211-220.
PubMed
4) Tan CF, et al. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol 2007 ; 113 (5) : 535-542.
 
5) Yokoseki A, et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol 2008 ; 63 (4) : 538-542.
PubMed
6) Chio A, et al. ALS/FTD phenotype in two Sardinian families carrying both C9ORF72 and TARDBP mutations. J Neurol Neurosurg Psychiatry 2012 ; 83 (7) : 730-733.
PubMed
7) Fujita Y, et al. Different clinical and neuropathologic phenotypes of familial ALS with A315E TARDBP mutation. Neurology 2011 ; 77 (15) : 1427-1431.
PubMed
8) Iida A, et al. Large-scale screening of TARDBP mutation in amyotrophic lateral sclerosis in Japanese. Neurobiol Aging 2010 ; 33 : 786-790.
PubMed
9) Kamada M, et al. Screening for TARDBP mutations in Japanese familial amyotrophic lateral sclerosis. J Neurol Sci 2009 ; 284 (1-2) : 69-71.
PubMed
10) Nozaki I, et al. Familial ALS with G298S mutation in TARDBP : A comparison of CSF tau protein levels with those in sporadic ALS. Intern Med 2010 ; 49 (12) : 1209-1212.
PubMed
11) Tamaoka A, et al. TDP-43 M337V mutation in familial amyotrophic lateral sclerosis in Japan. Intern Med 2010 ; 49 (4) : 331-334.
PubMed
12) Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008 ; 319 (5870) : 1668-1672.
PubMed
13) Corcia P, et al. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology 2012 ; 78 (19) : 1519-1526.
 
14) Benajiba L, et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol 2009 ; 65 (4) : 470-473.
PubMed
15) Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 2008 ; 64 (1) : 60-70.
PubMed
16) Freibaum BD, et al. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res 2010 ; 9 (2) : 1104-1120.
PubMed
17) Polymenidou M, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 2011 ; 14 (4) : 459-468.
PubMed
18) Shiga A, et al. Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS. PLoS One 2012 ; 7 (8) : e43120.
PubMed
19) Avendano-Vazquez SE, et al. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev 2012 ; 26 (15) : 1679-1684.
PubMed
20) Lee EB, et al. Gains or losses : Molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci 2012 ; 13 (1) : 38-50.
PubMed
・ 横関明男ほか. ALS10 (TARDBP遺伝子変異によるALS). 神経内科 2012 ; 76 (5) : 489-496.
 
・ 特集 神経変性疾患におけるTDP-43. 最新医学 2010 ; 65 (7).
 
P.180 掲載の参考文献
1) Kwiatkowski TJ Jr, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009 ; 323 : 1205-1208.
PubMed
2) Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009 ; 323 : 1208-1211.
PubMed
3) Lagier-Tourenne C, Cleveland DW. Rethinking ALS : The FUS about TDP-43. Cell 2009 ; 136 : 1001-1004.
PubMed
4) Mackenzie IR, et al. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010 ; 9 : 995-1007.
PubMed
5) Suzuki N, et al. FALS with FUS mutation in Japan, with early onset, rapid progress and basophilic inclusion. J Hum Genet 2010 ; 55 : 252-254.
PubMed
6) Suzuki N, et al. FUS/TLS-immunoreactive neuronal and glial cell inclusions increase with disease duration in familial amyotrophic lateral sclerosis with an R521C FUS/TLS mutation. J Neuropathol Exp Neurol 2012 ; 71 : 779-788.
PubMed
7) Tateishi T, et al. Multiple system degeneration with basophilic inclusions in Japanese ALS patients with FUS mutation. Acta Neuropathol 2010 ; 119 : 355-364.
PubMed
8) Mackenzie IR, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration : An update. Acta Neuropathol 2010 ; 119 : 1-4.
PubMed
9) Mackenzie IR, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011 ; 122 : 111-113.
PubMed
10) Polymenidou M, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 2011 ; 14 : 459-468.
PubMed
11) Lagier-Tourenne C, et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci 2012 ; 15 : 1488-1497.
PubMed
12) Ito H, et al. Optineurin is co-localized with FUS in basophilic inclusions of ALS with FUS mutation and in basophilic inclusion body disease. Acta Neuropathol 2011 ; 121 : 555-557.
PubMed
P.186 掲載の参考文献
1) Li Y, et al. Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains. Mol Cell Biol 1998 ; 18 : 1601-1610.
PubMed
2) Rezaie T, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science 2002 ; 295 : 1077-1079.
PubMed
3) Zhu G, et al. Optineurin negatively regulates TNFalpha-induced NF-kappaB activation by competing with NEMO for ubiquitinated RIP. Curr Biol 2007 ; 17 : 1438-1443.
PubMed
4) Wild P, et al. Phosphorylation of the autophagy receptor optineurin restricts salmonella growth. Science 2011 ; 333 : 228-233.
PubMed
5) Huqun, et al. A quantitatively-modeled homozygosity mapping algorithm, qHomozygosityMapping, utilizing whole genome single nucleotide polymorphism genotyping data. BMC Bioinformatics 2010 ; 11 Suppl7 : S5.
 
6) Huqun, et al. Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med 2007 ; 175 : 263-268.
PubMed
7) Maruyama H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010 ; 465 : 223-226.
PubMed
8) Sugihara K, et al. Screening for OPTN mutations in amyotrophic lateral sclerosis in a mainly Caucasian population. Neurobiol Aging 2011 ; 32 : 1923. e9-10.
 
9) Ueno H, et al. Severe brain atrophy after long-term survival seen in siblings with familial amyotrophic lateral sclerosis and a mutation in the optineurin gene : A case series. J Med Case Reports 2011 ; 5 : 573.
 
10) Sakaguchi T, et al. Optineurin with amyotrophic lateral sclerosis-related mutations abrogates inhibition of interferon regulatory factor-3 activation. Neurosci Lett 2011 ; 505 : 279-281.
PubMed
11) Ito H, et al. Clinicopathologic study on an ALS family with a heterozygous E478G optineurin mutation. Acta Neuropathol 2011 ; 122 : 223-229.
 
12) Ito H, et al. Optineurin is co-localized with FUS in basophilic inclusions of ALS with FUS mutation and in basophilic inclusion body disease. Acta Neuropathol 2011 ; 121 : 555-557.
PubMed
P.193 掲載の参考文献
1) McCarthy MI, et al. Genome-wide association studies : Potential next steps on a genetic journey. Hum Mol Genet 2008 ; 17 : R156-165.
PubMed
2) Visscher PM, et al. Five years of GWAS discovery. Am J Hum Genet 2012 ; 90 : 7-24.
PubMed
3) Frazer KA, et al. A second generation human haplotype map of over 3. 1 million SNPs. Nature 2007 ; 449 : 851-861.
PubMed
4) Schymick JC, et al. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls : First stage analysis and public release of data. Lancet Neurol 2007 ; 6 : 322-328.
PubMed
5) Dunckley T, et al. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med 2007 ; 357 : 775-788.
PubMed
6) van Es MA, et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis : A genome-wide association study. Lancet Neurol 2007 ; 6 : 869-877.
PubMed
7) van Es MA, et al. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet 2008 ; 40 : 29-31.
PubMed
8) van Es MA, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 2009 ; 41 : 1083-1087.
PubMed
9) Laaksovirta H, et al. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland : A genome-wide association study. Lancet Neurol 2010 ; 9 : 978-985.
PubMed
10) Shatunov A, et al. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries : A genome-wide association study. Lancet Neurol 2010 ; 9 : 986-994.
PubMed
11) Cronin S, et al. Screening for replication of genome-wide SNP associations in sporadic ALS. Eur J Hum Genet 2009 ; 17 : 213-218.
PubMed
12) Fernandez-Santiago R, et al. No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort. Neurobiol Aging 2011 ; 32 : 551 e551-554.
 
13) Iida A, et al. A functional variant in ZNF512B is associated with susceptibility to amyotrophic lateral sclerosis in Japanese. Hum Mol Genet 2011 ; 20 : 3684-3692.
PubMed
14) Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011 ; 72 : 257-268.
PubMed
15) Manolio TA, et al. Finding the missing heritability of complex diseases. Nature 2009 ; 461 : 747-753.
PubMed
16) Klein RJ, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005 ; 308 : 385-389.
PubMed
17) Costa V, et al. RNA-Seq and human complex diseases : Recent accomplishments and future perspectives. Eur J Hum Genet 2013 ; 21 : 134-142.
PubMed
18) Diekstra FP, et al. Mapping of gene expression reveals CYP27A1 as a susceptibility gene for sporadic ALS. PLoS One 2012 ; 7 : e35333.
PubMed
19) Stranger BE, et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007 ; 315 : 848-853.
PubMed
20) A map of human genome variation from population-scale sequencing. Nature 2010 ; 467 : 1061-1073.
PubMed
P.202 掲載の参考文献
1) Kwong L, et al. TDP-43 proteinopathy : The neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathologica 2007 ; 114 : 63-70.
PubMed
2) Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Annals of Neurology 2008 ; 64 : 60-70.
PubMed
3) Deng H-X, et al. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Annals of Neurology 2010 ; 67 : 739-748.
PubMed
4) Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis : What do we really know? Nat Rev Neurol 2011 ; 7 : 603-615.
PubMed
5) Manolio TA, et al. Finding the missing heritability of complex diseases. Nature 2009 ; 461 : 747-753.
PubMed
6) Fang F, et al. Familial aggregation of amyotrophic lateral sclerosis. Ann Neurol 2009 ; 66 : 94-99.
PubMed
7) Al-Chalabi A, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry 2010 ; 81 : 1324-1326.
 
8) Falconer DS. The inheritance of liability to certain diseases, estimated from the incidence among relatives. Annals of Human Genetics 1965 ; 29 : 51-76.
 
9) Kondo K, Tsubaki T. Genetic and environmental factor in the pathogenesis of motor neuron disease ; (1) Identification of the index cases. Jinrui Idengaku Zasshi 1974 ; 19 : 107-109.
 
10) Aoki M, et al. Clinical genetics of amyotrophic lateral sclerosis in Japan : An update. Rinsho Shinkeigaku 2012 ; 52 : 844-847.
PubMed
11) Majounie E, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia : A crosssectional study. Lancet Neurol 2012 ; 11 : 323-330.
PubMed
12) Ishiura H, et al. C9ORF72 repeat expansion in amyotrophic lateral sclerosis in the Kii peninsula of Japan. Arch Neurol 2012 ; 69 : 1154-1158.
PubMed
13) Ogaki K, et al. Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. Neurobiol Aging 2012 ; 33 : 2527. e11-16.
 
14) Gijselinck I, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum : A gene identification study. The Lancet Neurology 2012 ; 11 : 54-65.
 
15) Boeve BF, et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 2012 ; 135 : 765-783.
 
16) Millecamps S, et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis : Genotype-phenotype correlations. J Med Genet 2010 ; 47 : 554-560.
PubMed
17) Stewart H, et al. Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol 2012 ; 123 : 409-417.
PubMed
18) Guerreiro R, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013 ; 368 : 117-127.
PubMed

V. ALSの病態

P.212 掲載の参考文献
1) Takuma H, et al. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol 1999 ; 46 : 806-815.
PubMed
2) Kawahara Y, et al. Glutamate receptors : RNA editing and death of motor neurons. Nature 2004 ; 427 : 801.
PubMed
3) Kwak S, Kawahara Y. Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J Mol Med 2005 ; 83 : 110-120.
PubMed
4) Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006 ; 351 : 602-611 .
PubMed
5) Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006 ; 314 : 130-133.
 
6) Yamashita T, et al. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat Commun 2012 ; 3 : 1307.
PubMed
7) 郭伸. RNA editing活性低下とTDP-43 病理-孤発性ALS運動ニューロンにおける疾患特異的両分子異常の分子連関. BRAIN and NERVE 2012 ; 64 (5) : 549-556.
 
8) Hideyama T, et al. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol Dis 2012 ; 45 : 1121-1128.
PubMed
9) Kawahara Y, et al. Underediting of GluR2 mRNA, a neuronal death inducing molecular change in sporadic ALS, does not occur in motor neurons in ALS1 or SBMA. Neurosci Res 2006 ; 54 : 11-14.
PubMed
10) Suzuki T, et al. Recent advances in the study of AMPA receptors. Nihon Yakurigaku Zasshi 2003 ; 122 : 515-526.
 
11) Hideyama T, et al. Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. J Neurosci 2010 ; 30 : 11917-11925.
PubMed
12) Hideyama T, Kwak S. When Does ALS Start? ADAR2-GluA2 Hypothesis for the Etiology of Sporadic ALS. Front Mol Neurosci 2011 ; 4 : 33.
PubMed
13) Aizawa H, et al. TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol 2010 ; 120 : 75-84.
PubMed
14) Mackenzie IR, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007 ; 61 : 427-434.
PubMed
15) Tan CF, et al. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol 2007 ; 113 : 535-542.
 
16) Atsuta N, et al. Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. J Neurol Sci 2009 ; 276 : 163-169.
PubMed
17) Eisen A, et al. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 1993 ; 16 : 27-32.
PubMed
18) Tomlinson BE, Irving D. The numbers of limb motor neurons in the human lumbosacral cord throughout life. J Neurol Sci 1977 ; 34 : 213-219.
 
19) Hideyama T, Kwak S. Co-occurrence of TDP-43 mislocalization with reduced activity of an RNA editing enzyme, ADAR2, in aged mouse motor neurons. PLoS ONE 2012 ; 7 : e43469.
PubMed
20) Sebastiani P, et al. RNA editing genes associated with extreme old age in humans and with lifespan in C. elegans. PLoS One 2009 ; 4 : e8210.
 
21) Yamashita T, et al. The abnormal processing of TDP-43 is not an upstream event of reduced ADAR2 activity in ALS motor neurons. Neurosci Res 2012 ; 73 : 153-160.
PubMed
22) Lomen-Hoerth C, et al. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003 ; 60 : 1094-1097.
PubMed
23) Ringholz GM, et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005 ; 65 : 586-590.
PubMed
24) Mackenzie IR, et al. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010 ; 9 : 995-1007.
PubMed
25) Lagier-Tourenne C, et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci 2012 : 15 : 1488-1497.
PubMed
26) Dormann D, et al. Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J 2012 ; 31 : 4258-4275.
 
27) Neumann M, et al. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 2011 ; 134 : 2595-2609.
PubMed
28) Neumann M, et al. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations. Acta Neuropathol 2012 ; 124 : 705-716.
PubMed
P.222 掲載の参考文献
1) Holzbaur EL. Motor neurons rely on motor proteins. Trends Cell Biol 2004 ; 14 (5) : 233-240.
PubMed
2) De Vos KJ, et al. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 2008 ; 31 : 151-173.
PubMed
3) Tanaka FK, et al. [Role of axonal transport in ALS]. Rinsho Shinkeigaku 2011 ; 51 (11) : 189-191.
 
4) Hirokawa N, Takemura R. Molecular motors in neuronal development, intracellular transport and diseases. Curr Opin Neurobiol 2004 ; 14 (5) : 564-573.
PubMed
5) Hafezparast M, et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 2003 ; 300 (5620) : 808-812.
PubMed
6) Puls I, et al. Mutant dynactin in motor neuron disease. Nat Genet 2003 ; 33 (4) : 455-456.
PubMed
7) Lai C, et al. The G59S mutation in p150 (glued) causes dysfunction of dynactin in mice. J Neurosci 2007 ; 27 (51) : 13982-13990.
PubMed
8) LaMonte BH, et al. Disruption of dynein / dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 2002 ; 34 (5) : 715-277.
PubMed
9) Bilsland LG, et al. Deficits in axonal transport precede ALS symptoms in vivo. Proc Natl Acad Sci U S A 2010 ; 107 (47) : 20523-20528.
PubMed
10) Sasaki S, Iwata M. Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology 1996 ; 47 (2) : 535-540.
PubMed
11) Jiang YM, et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann Neurol 2005 ; 57 (2) : 236-251.
PubMed
12) Jiang YM, et al. Gene expressions specifically detected in motor neurons (dynactin 1, early growth response 3, acetyl-CoA transporter, death receptor 5, and cyclin C) differentially correlate to pathologic markers in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2007 ; 66 (7) : 617-627.
PubMed
13) Morfini G, et al. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat Neurosci 2006 ; 9 (7) : 907-916.
PubMed
14) Katsuno M, et al. Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. J Neurosci 2006 ; 26 (47) : 12106-12117.
PubMed
15) Lorson CL, et al. Spinal muscular atrophy : Mechanisms and therapeutic strategies. Hum Mol Genet 2010 ; 19 (R1) : R111-118.
 
16) Dale JM, et al. The spinal muscular atrophy mouse model, SMA Δ 7, displays altered axonal transport without global neurofilament alterations. Acta Neuropathol 2011 ; 122 (3) : 331-341.
 
17) Salinas S, et al. Hereditary spastic paraplegia : Clinical features and pathogenetic mechanisms. Lancet Neurol 2008 ; 7 (12) : 1127-1138.
PubMed
P.232 掲載の参考文献
1) Choi CI, et al. Effects of estrogen on lifespan and motor functions in female hSOD1 G93A transgenic mice. J Neurol Sci 2008 ; 268 : 40-47.
PubMed
2) Nagata T, et al. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol Res 2007 ; 29 : 772-776.
PubMed
3) Suzuki M, et al. Immunohistochemical studies of vascular endothelial growth factor in skin of patients with amyotrophic lateral sclerosis. J Neurol Sci 2009 ; 285 : 125-129.
PubMed
4) Kim SM, et al. Amyotrophic lateral sclerosis is associated with hypolipidemia at the presymptomatic stage in mice. PLoS One 2011 ; 6 : e17985 (p.1-5).
 
5) Andersson S, et al. Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc Natl Acad Sci U S A 2005 ; 102 : 3857-3862.
PubMed
6) Abe K, et al. Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. Neurol Res 1997 ; 19 (2) : 124-128.
 
7) Mimoto T, et al. Impaired antioxydative Keap1 / Nrf2 system and the downstream stress protein responses in the motor neuron of ALS model mice. Brain Res 2012 ; 1446 : 109-118.
PubMed
8) Abe K, et al. Ischemic delayed neuronal death : A mitochondrial hypothesis. Stroke 1995 ; 26 : 1478-1489.
 
9) Warita H, et al. Oxidative damage to mitochondrial DNA in spinal motoneurons of transgenic ALS mice. Brain Res Mol Brain Res 2001 ; 89 : 147-152.
PubMed
10) Kaal EC, et al. Chronic mitochondrial inhibition induces selective motoneuron death in vitro : A new model for amyotrophic lateral sclerosis. J Neurochem 2000 ; 74 : 1158-1165.
PubMed
11) Murakami T, et al. Early decrease of mitochondrial DNA repair enzymes in spinal motor neurons of presymptomatic transgenic mice carrying a mutant SOD1 gene. Brain Res 2007 ; 1150 : 182-189.
PubMed
12) Murakami T, et al. Hypoxic induction of vascular endothelial growth factor is selectively impaired in mice carrying the mutant SOD1 gene. Brain Res 2003 ; 989 : 231-237.
PubMed
13) Ilieva H, et al. Sustained induction of survival p-AKT and p-ERK signals after transient hypoxia in mice spinal cord with G93A mutant human SOD1 protein. J Neurol Sci 2003 ; 215 : 57-62.
PubMed
14) Morimoto N, et al. Increased autophagy in transgenic mice with a G93A mutant SOD1 gene. Brain Res 2007 ; 1167 : 112-117.
PubMed
15) Tian F, et al. In vivo optical imaging of motor neuron autophagy in a mouse model of amyotrophic lateral sclerosis. Autophagy 2011 ; 7 : 985-992.
 
16) Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler 2006 ; 7 : 241-245.
PubMed
P.237 掲載の参考文献
1) Kawamata T, et al. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992 ; 140 (3) : 691-707.
PubMed
2) Turner MR, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis : An [11C] (R) -PK11195 positron emission tomography study. Neurobiol Dis 2004 ; 15 (3) : 601-609.
PubMed
3) Nagy D, et al. Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J Neurosci Res 1994 ; 38 (3) : 336-347.
PubMed
4) Boillee S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006 ; 312 (5778) : 1389-1392.
PubMed
5) Yamanaka K, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008 ; 11 (3) : 251-253.
PubMed
6) Beers DR, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2006 ; 103 (43) : 16021-16026.
PubMed
7) Hensley K, et al. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis 2003 ; 14 (1) : 74-80.
PubMed
8) Yoshihara T, et al. Differential expression of inflammation-and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 2002 ; 80 (1) : 158-167.
 
9) Hensley K, et al. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem 2002 ; 82 (2) : 365-374.
PubMed
10) Butovsky O, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 2012 ; 122 (9) : 3063-3087.
PubMed
11) Almer G, et al. Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1999 ; 72 (6) : 2415-2425.
 
12) Alexianu ME, et al. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 2001 ; 57 (7) : 1282-1289.
 
13) Henkel JS, et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 2004 ; 55 (2) : 221-235.
PubMed
14) Henkel JS, et al. Microglia in ALS : The good, the bad, and the resting. J Neuroimmune Pharmacol 2009 ; 4 (4) : 389-398.
PubMed
15) Chiu IM, et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci U S A 2008 ; 105 (46) : 17913-17918.
 
16) Howland DS, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A 2002 ; 99 (3) : 1604-1609.
 
17) Rothstein JD, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995 ; 38 (1) : 73-84.
PubMed
18) Haidet-Phillips AM, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 2011 ; 29 (9) : 824-828.
PubMed
19) Lee Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012 ; 487 (7408) : 443-448.
PubMed
20) Kang SH, et al. NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. Neuron 2010 ; 68 (4) : 668-681.
 
・ Ilieva H, et al. Non-cell autonomous toxicity in neurodegenerative disorders : ALS and beyond. J Cell Biol 2009 ; 187 : 761-772.
PubMed
・ Phillips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis : Role of glial activation in motor neuron disease. Lancet Neurol 2011 ; 10 : 253-263.
 
・ Lasiene J, Yamanaka K. Glial cells in amyotrophic lateral sclerosis. Neurol Res Int 2011 ; 718987.
PubMed
P.244 掲載の参考文献
1) Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 2008 ; 64 : 60-70.
PubMed
2) Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006 ; 351 : 602-611.
PubMed
3) Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006 ; 314 : 130-133.
 
4) Tsuji H, et al. Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain 2012 ; 135 : 3380-3391.
PubMed
5) Tsuji H. et al. Epitope mapping of antibodies against TDP-43 and detection of proteaseresistant fragments of pathological TDP-43 in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Biochem Biophys Res Commun 2012 ; 417 : 116-121.
PubMed
6) Kwiatkowski TJ Jr, et al. Mutations in the FUS / TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009 ; 323 : 1205-1208.
PubMed
7) Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009 ; 323 : 1208-1211.
PubMed
8) Munoz DG, et al. FUS pathology in basophilic inclusion body disease. Acta Neuropathol 2009 ; 118 : 617-627.
PubMed
9) Neumann M, et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 2009 ; 132 : 2922-2931.
 
10) Dormann D, et al. Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J 2012 ; 31 : 4258-4275.
 
11) Nonaka T, et al. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet 2009 ; 18 : 3353-3364.
PubMed
12) Arai T, et al. Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology 2010 ; 30 : 170-181.
PubMed
13) Hasegawa M, et al. Molecular dissection of TDP-43 proteinopathies. J Mol Neurosci 2011 ; 45 : 480-485.
PubMed
14) Luk KC, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012 ; 338 : 949-953.
PubMed
15) Masuda-Suzukake M, et al. Prion-like spreading of pathological α-synuclein in brain. Brain 2013 ; 136 : 1128-1138.
 
P.250 掲載の参考文献
1) Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000 ; 290 : 1717-1721.
PubMed
2) Klionsky DJ. Autophagy : From phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007 ; 8 : 931-937.
PubMed
3) Tsukada M, Ohsumi Y. Isolation and characterization of autophagy-defective mutants of Saccharomyces cerevisiae. FEBS Lett 1993 ; 333 : 169-174.
PubMed
4) Kuma A, et al. The role of autophagy during the early neonatal starvation period. Nature 2004 ; 432 : 1032-1036.
PubMed
5) Komatsu M, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006 ; 441 : 880-884.
PubMed
6) Hara T, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006 ; 441 : 885-889.
PubMed
7) Kamada Y, et al. Tor-mediated induction of autophagy via an Apg1 protein kinase complex. J Cell Biol 2000 ; 150 : 1507-1513.
PubMed
8) Morimoto N, et al. Increased autophagy in transgenic mice with a G93A mutant SOD1 gene. Brain Res 2007 ; 1167 : 112-117.
PubMed
9) Li L, et al. Altered macroautophagy in the spinal cord of SOD1 mutant mice. Autophagy 2008 ; 4 : 290-293.
PubMed
10) Rusten TE, Simonsen A. ESCRT functions in autophagy and associated disease. Cell Cycle 2008 ; 7 : 1166-1172.
PubMed
11) Sasaki S. Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2011 ; 70 : 349-359.
PubMed
12) Mizuno Y, et al. Immunoreactivities of p62, an ubiquitin-binding protein, in the spinal anterior horn cells of patients with amyotrophic lateral sclerosis. J Neurol Sci 2006 ; 249 : 13-18.
PubMed
13) Nakano I, et al. On the possibility of autolysosomal processing of skein-like inclusions. Electron microscopic observation in a case of amyotrophic lateral sclerosis. J Neurol Sci 1993 ; 120 : 54-59.
 
14) Ferrucci M, et al. A systematic study of brainstem motor nuclei in a mouse model of ALS, the effects of lithium. Neurobiol Dis 2010 ; 37 : 370-383.
 
15) Fornai F, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008 ; 105 : 2052-2057.
PubMed
16) Shin JH, et al. Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis. Mol Pharmacol 2007 ; 71 : 965-975.
 
17) Caldero J, et al. Lithium prevents excitotoxic cell death of motoneurons in organotypic slice cultures of spinal cord. Neuroscience 2010 ; 165 : 1353-1369.
PubMed
18) Feng H, et al. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 2008 ; 155 : 567-572.
 
19) Gill A, et al. No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS. PLoS One 2009 ; 4 : e6489.
 
20) Pizzasegola C, et al. Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph Lateral Scler 2009 ; 10 : 221-228.
 
21) Chio A, et al. Lithium carbonate in amyotrophic lateral sclerosis. Lack of efficacy in a dose-finding trial. Neurology 2010 ; 75 : 619-625.
 
22) Aggarwal SP, et al ; Northeast and Canadian Amyotrophic Lateral Sclerosis consortia. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis : A randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010 ; 9 : 481-488.
PubMed
P.258 掲載の参考文献
1) Rosen DR, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993 ; 362 : 59-62.
PubMed
2) Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006 ; 314 : 130-133.
 
3) Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008 ; 319 : 1668-1672.
PubMed
4) Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009 ; 323 : 1208-1211.
PubMed
5) Kwiatkowski TJ Jr, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009 ; 323 : 1205-1208.
PubMed
6) DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011 ; 72 : 245-256.
PubMed
7) Feiguin F, et al. Depletion of TDP-43 affects Drosophila motoneurons terminal synapsis and locomotive behavior. FEBS Lett 2009 ; 583 : 1586-1592.
PubMed
8) Li Y, et al. A Drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci U S A 2010 ; 107 : 3169-3174.
 
9) Ritson G, et al. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci 2010 ; 30 : 7729-7739.
 
10) Ash P, et al. Neurotoxic effects of TDP-43 overexpression in C.elegans. Hum Mol Genet 2010 ; 19 : 3206-3218.
 
11) Kraemer BC, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol 2010 ; 119 : 409-419.
PubMed
12) Ayala YM, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J 2011 ; 30 : 277-288.
PubMed
13) Chiang PM, et al. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc Natl Acad Sci U S A 2010 ; 107 : 16320-16324.
PubMed
14) Wegorzewska I, et al. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 2009 ; 106 : 18809-18814.
PubMed
15) Swarup V, et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain 2011 ; 134 : 2620-2626.
 
16) Wils H, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 2010 ; 107 : 3858-3863.
PubMed
17) Tsai KJ, et al. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J Exp Med 2010 ; 207 : 1661-1673.
 
18) Igaz LM, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest 2011 ; 121 : 726-738.
PubMed
19) Shan X, et al. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc Natl Acad Sci U S A 2010 ; 107 : 16325-16330.
PubMed
20) Xu YF, et al. Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol Neurodegener 2011 ; 6 : 73.
PubMed
21) Zhou H, et al. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet 2010 ; 6 : e1000887.
PubMed
22) Van Hoecke A, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 2012 ; 18 : 1418-1422.
PubMed
23) Wang IF, et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. PNAS 2012 ; 109 : 15024-15029.
PubMed
24) Uchida A, et al. Non-human primate model of amyotrophic lateral sclerosis with cytoplasmic mislocalization of TDP-43. Brain 2012 ; 135 : 833-846.
PubMed
25) Gitcho MA, et al. TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol 2009 ; 118 : 633-645.
PubMed
26) Rabin SJ, et al. Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology. Hum Mol Genet 2010 ; 19 : 313-328.
 
P.264 掲載の参考文献
1) Andersen PM, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) --revised report of an EFNS task force. Eur J Neurol 2012 ; 19 : 360-375.
 
2) Tarasiuk J, et al. CSF markers in amyotrophic lateral sclerosis. J Neural Transm 2012 ; 119 : 747-757.
PubMed
3) Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006 ; 51 : 602-611.
 
4) Steinacker P, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 2008 ; 65 : 1481-1487.
PubMed
5) Kasai T, et al. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol 2009 ; 117 : 55-62.
PubMed
6) Noto Y, et al. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis : Specificity, ensitivity, and a possible prognostic value. Amyotroph Lateral Scler 2011 ; 12 : 140-143.
 
7) Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 2008 ; 64 : 60-70.
PubMed
8) Foulds PG, et al. Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. Acta Neuropathol 2009 ; 118 : 647-658.
PubMed
9) Mitchell RM, et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009 ; 72 : 14-19.
PubMed
10) Tanaka M, et al. Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2006 ; 65 : 816-825.
PubMed
11) Tateishi T, et al. CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. J Neuroimmunol 2010 ; 222 : 76-81.
 
12) Brettschneider J, et al. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006 ; 66 : 852-856.
PubMed
13) Ganesalingam J, et al. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 2011 ; 117 : 528-537.
PubMed
14) Ganesalingam J, et al. pNfH is a promising biomarker for ALS. Amyotroph Lateral Scler Frontotemporal Degener 2013 ; 14 : 46-149.
 
15) Okamoto K, et al. Bunina bodies in amyotrophic lateral sclerosis immunostained with rabbit anti-cystatin C serum. Neurosci Lett 1993 ; 162 : 125-128.
PubMed
16) Wilson ME, et al. Cystatin C : A candidate biomarker for amyotrophic lateral sclerosis. PLoS One 2010 ; 5 : e15133.
PubMed

VI. ALSおよび関連運動ニューロン疾患の治療と介護

P.274 掲載の参考文献
1) Lunn JS, et al. Stem cell technology for the study and treatment of motor neuron diseases. Regen Med 2011 ; 6 : 201-213.
 
2) Corti S, et al. Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. Brain 2010 ; 133 : 465-481.
PubMed
3) Xu L, et al. Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation 2006 ; 82 : 865-875.
PubMed
4) Glass JD, et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis : Results of a phase I trial in 12 patients. Stem Cells 2012 ; 30 : 1144-1151.
PubMed
5) Di Giorgio FP, et al. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 2007 ; 10 : 608-614.
 
6) Nagai M, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007 ; 10 : 615-622.
PubMed
7) Yamanaka K, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008 ; 11 : 251-253.
PubMed
8) Ebert AD, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009 ; 457 : 277-280.
PubMed
9) Bilican B, et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A 2012 ; 109 : 5803-5808.
PubMed
10) Egawa N, et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 2012 ; 4 : 145ra104.
PubMed
11) Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007 ; 131 : 861-872.
PubMed
12) Dimos JT, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008 ; 321 : 1218-1221.
PubMed
13) Nguyen HN, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 2011 ; 8 : 267-280.
PubMed
14) Byers B, et al. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS One 2011 ; 6 : e26159. Epub 2011 Nov16.
 
15) Seibler P, et al. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J Neurosci 2011 ; 31 : 5970-5976.
PubMed
16) Devine MJ, et al. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun 2011 ; 2 : 440. doi : 10. 1038/ncomms1453.
 
17) HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 2012 ; 11 : 264-278.
PubMed
18) Ku S, et al. Friedreich's ataxia induced pluripotent stem cells model intergenerational GAA・TTC triplet repeat instability. Cell Stem Cell 2010 ; 7 : 631-637.
 
P.280 掲載の参考文献
1) Schenk D, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999 ; 400 (6740) : 173-177.
PubMed
2) 大野美樹, 漆谷真. 神経変性疾患に対する免疫療法の現状. 細胞工学 2011 ; 30 (10) : 1054-1059.
Medical*Online
3) Rosen DR, et al. Mutations in Cu / Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993 ; 362 (6415) : 59-62.
PubMed
4) Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006 ; 351 (3) : 602-611. Epub 2006/11/07.
 
5) Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006 ; 314 (5796) : 130-133.
PubMed
6) Ilieva H, et al. Non-cell autonomous toxicity in neurodegenerative disorders : ALS and beyond. J Cell Biol 2009 ; 187 (6) : 761-772.
PubMed
7) Rakhit R, et al. An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat Med 2007 ; 13 (6) : 754-759.
PubMed
8) Urushitani M, et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci 2006 ; 9 (1) : 108-118. Epub 2005/12/22.
 
9) Papadeas ST, et al. Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo. Proc Natl Acad Sci U S A 2011 ; 108 (43) : 17803-17808. Epub 2011/10/05.
 
10) Urushitani M, et al. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2007 ; 104 (7) : 2495-2500. Epub 2007/02/06.
 
11) Gros-Louis F, et al. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 2010 ; 113 (5) : 1188-1199. Epub 2010/03/30.
PubMed
12) Liu HN, et al. Targeting of monomer/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis. J Neurosci 2012 ; 32 (26) : 8791-8799.
PubMed
13) Zhang YJ, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A 2009 ; 106 (18) : 7607-7612. Epub 2009/04/23.
 
14) Fujimura-Kiyono C, et al. Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011 ; 82 (11) : 1244-1249. Epub 2011/09/17.
 
15) Furukawa Y, et al. A seeding reaction recapitulates intracellular formation of Sarkosylinsoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem 2011 ; 286 (21) : 18664-18672. Epub 2011/04/02.
 
・ Shibata N, et al. Cu/Zn superoxide dismutase-like immunoreactivity in Lewy body-like inclusions of sporadic amyotrophic lateral sclerosis. Neurosci Lett 1994 ; 179 (1-2) : 149-152.
 
・ Bosco DA, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 2010 ; 13 (11) : 1396-1403. Epub 2010/10/19.
 
・ Mackenzie IR, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007 ; 61 (5) : 427-434.
PubMed
P.287 掲載の参考文献
1) Yamanaka K, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008 ; 11 : 251-253.
PubMed
2) Lioy DT, et al. A role for glia in the progression of Rett's syndrome. Nature 2011 ; 475 : 497-500.
PubMed
3) Turner MR, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis : An [11C] (R) -PK11195 positron emission tomography study. Neurobiol Dis 2004 ; 5 (3) : 601-609.
 
4) Casula M, et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 2011 ; 179 : 233-243.
PubMed
5) Dibaj P, et al. Influence of methylene blue on microglia-induced inflammation and motor neuron degeneration in the SOD1G93A model for ALS. PLoS ONE 2012 ; 7 : e43963.
PubMed
6) Takeuchi H, et al. Tumor necrosis factor-α induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 2006 ; 281 : 21362-21368.
 
7) Takeuchi H, et al. Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease. PLoS One 2011 ; 6 : e21108.
PubMed
8) Doi Y, et al. Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid β neurotoxicity in in vitro and in vivo models of Alzheimer's disease. Am J Pathol 2009 ; 175 : 2121-2132.
 
9) Liu S, et al. TLR2 is a primary receptor for Alzheimer's amyloid β peptide to trigger neuroinflammatory activation. J Immunol 2012 ; 188 : 1098-1107.
 
10) Willemen HL, et al. MicroRNA-124 as a novel treatment for persistent hyperalgesia. J Neuroinflammation 2012 ; 9 : 143.
PubMed
11) Guerrero AR, et al. Blockade of interleukin-6 signaling inhibits the classic pathway and promotes an alternative pathway of macrophage activation after spinal cord injury in mice. J Neuroinflammation 2012 ; 9 : 40.
PubMed
P.293 掲載の参考文献
1) Kennedy WR, et al. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968 ; 18 : 671-680.
PubMed
2) Katsuno M, et al. Molecular pathophysiology and disease-modifying therapies for spinal and bulbar muscular atrophy. Arch Neurol 2012 ; 69 : 436-440.
PubMed
3) Adachi H, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 2005 ; 128 : 659-670.
PubMed
4) Jochum T, et al. Toxic and non-toxic aggregates from the SBMA and normal forms of androgen receptor have distinct oligomeric structures. Biochim Biophys Acta 2012 ; 1822 : 1070-1078.
PubMed
5) Katsuno M, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002 ; 35 : 843-854.
 
6) Chevalier-Larsen ES, et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 2004 ; 24 : 4778-4786.
 
7) Katsuno M, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003 ; 9 : 768-773.
 
8) Banno H, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 2009 ; 65 : 140-150.
PubMed
9) Katsuno M, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study) : A multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010 ; 9 : 875-884.
PubMed
10) Fernandez-Rhodes LE, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy : A randomised placebo-controlled trial. Lancet Neurol 2011 ; 10 : 140-147.
PubMed
11) Nedelsky NB, et al. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 2010 ; 67 : 936-952.
 
12) Yang Z, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 2007 ; 13 : 348-353.
PubMed
13) Palazzolo I, et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 2009 ; 63 : 316-328.
 
14) Waza M, et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005 ; 11 : 1088-1095.
PubMed
15) Katsuno M, et al. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci U S A 2005 ; 102 : 16801-16806.
PubMed
16) Montie HL, et al. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2009 ; 18 : 1937-1950.
 
17) Miyazaki Y, et al. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med 2012 ; 18 : 1136-1141.
PubMed
18) Sopher BL, et al. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 2004 ; 41 : 687-699.
PubMed
19) Minamiyama M, et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2004 ; 13 : 1183-1192.
 
20) Minamiyama M, et al. Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by expanded polyglutamine repeat tract. Nat Med 2012 ; 18 : 1531-1538.
PubMed
21) Yamanaka K, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008 ; 11 : 251-253.
PubMed
22) Soraru G, et al. Spinal and bulbar muscular atrophy : Skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci 2008 ; 264 : 100-105.
PubMed
23) Yu Z, et al. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Invest 2006 ; 116 : 2663-2672.
 
24) Monks DA, et al. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc Natl Acad Sci U S A 2007 ; 104 : 18259-18264.
PubMed
25) Mo K, et al. Microarray analysis of gene expression by skeletal muscle of three mouse models of kennedy disease / spinal bulbar muscular atrophy. PLoS One 2010 ; 5 : e12922.
PubMed
26) Sambataro F, Pennuto M. Cell-autonomous and non-cell-autonomous toxicity in polyglutamine diseases. Prog Neurobiol 2012 ; 97 : 152-172.
PubMed
P.305 掲載の参考文献
1) Miller RG, et al. Practice parameter update : The care of the patient with amyotrophic lateral sclerosis : Drug, nutritional, and respiratory therapies (an evidence-based review) : Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009 ; 73 : 1218-1226.
 
2) Miller RG, et al. Practice parameter update : The care of the patient with amyotrophic lateral sclerosis : Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review) : Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009 ; 73 : 1227-1233.
 
3) Miller RG, et al. Practice parameter : The care of the patient with amyotrophic lateral sclerosis (an evidence-based review) : Report of the Quality Standards Subcommittee of the American Academy of Neurology : ALS Practice Parameters Task Force. Neurology 1999 ; 52 : 1311-1323.
 
4) Bradley WG, et al. Current management of ALS : Comparison of the ALS CARE Database and the AAN Practice Parameter. Neurology 2001 ; 57 : 500-504.
PubMed
5) Miller RG, et al. Outcomes research in amyotrophic lateral sclerosis : Lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database. Ann Neurol 2009 ; 65 Suppl 1 : S24-S28.
 
6) Mitsumoto H, et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord 2003 ; 4 : 177-185.
PubMed
7) Atkeson AD, et al. Patient-ventilator asynchrony with nocturnal noninvasive ventilation in ALS. Neurology 2011 ; 77 (6) : 549-555.
PubMed
8) Pioro EP, et al : Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010 ; 68 (5) : 693-702.
PubMed
9) Rabkin JG, et al. Modafinil treatment of fatigue in patients with ALS : A placebocontrolled study. Muscle Nerve 2009 ; 39 : 297-303.
 
10) Bello-Haas VD, et al. A Randomized Controlled Trial of Resistance Exercise in Individuals with ALS. Neurology 2007 ; 68 : 2003-2007.
PubMed
11) Scherer K, Bedlack RS. Diaphragm pacing in amyotrophic lateral sclerosis : A literature review. Muscle Nerve 2012 ; 46 (1) : 1-8.
PubMed
12) Mitsumoto H, et al. Randomized control trials in ALS : Lessons learned. Amyotroph Lateral Scler and Other Motor Neuron Disord 2004 ; 5 (Suppl 1) : 8-13.
 
13) Habib AA, Mitsumoto H. Emerging drugs for amyotrophic lateral sclerosis. Expert Opin Emerg Drugs 2011 ; 16 (3) : 537-558.
PubMed
14) Cudkowicz ME, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010 ; 11 (3) : 259-265.
PubMed
15) Cudkowicz M, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011 ; 17 (12) : 1652-1656.
PubMed
16) de Carvalho M, Pinto S. Lithium treatment in amyotrophic lateral sclerosis : Do we have enough trials? Expert Rev Neurother 2011 ; 11 (12) : 1693-1698.
PubMed
17) Gordon PH, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis : A phase III randomised trial. Lancet Neurol 2007 ; 6 : 1045-1053.
PubMed
P.313 掲載の参考文献
1) O'Brien T, et al. Motor neurone disease : A hospice perspective. BMJ 1992 ; 304 : 471-473.
PubMed
2) Oliver D. Ethical issues in palliative care--An overview. Palliat Med 1993 ; 7 (4 suppl) : 15-20.
 
3) Saunders C, et al. Hospice care in motor neuron disease. In : Saunders C, et al (editors). Hospice : the Living Idea. London : Edward Arnold ; 1981, pp.126-147.
 
4) Blackhall LJ. Amyotrpphic lateral sclerosis and palliative care : Where we are, and the road ahead. Muscle Nerve 2012 ; 45 : 311-318.
PubMed
5) Miller RG, et al. Practice parameter : The care of the patient with amyotrophic lateral sclerosis (an evidence-based review) : Report of the Quality Standards Subcommittee of the American Academy of Neurology : ALS Practice Parameters Task Force. Neurology 1999 ; 52 : 1311-1323.
 
6) Miller RG, et al. Practice parameter update : The care of the patient with amyotrophic lateral sclerosis : Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-cased review) : Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009 ; 73 : 1227-1233.
 
7) Bede P, et al. Palliative care in amyotrophic lateral sclerosis : A review of current international guidelines and initiatives. J Neurol Neurosurg Psychiatry 2011 ; 82 : 413-418.
PubMed
8) Phukan J, et al. The management of amyotrophic lateral sclerosis. J Neurol 2009 ; 256 : 176-186.
PubMed
9) EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis ; Andersen PM, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) --Revised report of an EFNS task force. Eur J Neurol 2012 ; 19 : 360-375.
 
10) Miller RG, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001 ; 56 : 843-848.
PubMed
11) 成田有吾 (編). 神経難病在宅療養ハンドブック-よりよい緩和ケア提供のために. 大阪 : メディカルレビュー社 ; 2011.
 
12) 日本緩和医療学会緩和医療ガイドライン作成委員会 (編). 国内で利用可能なオピオイドとその特徴, がん疼痛の薬物療法に関するガイドライン 2010年版, 東京 : 金原出版 ; 2010, pp.38-39.
 
13) Lynn L, et al. Perspectives on care at the close of life. Serving patients who may die soon and their families : The role of hospice and other services. JAMA 2001 ; 285 : 925-932.
 
14) Kawabata M, Kaneishi K. Continuous Subcutaneous Infusion of Compound Oxycodone for the Relief of Dyspnea in Terminally Ill Cancer Patients : A Retrospective Study. Am J Hosp Palliat Care 2012 [Epub ahead of print].
 
15) 日本緩和医療学会緩和医療ガイドライン作成委員会 (編). 苦痛緩和のための鎮静に関するガイドライン 2010年版, 東京 : 金原出版 ; 2010.
 
・ 成田有吾 (編). 神経難病在宅療養ハンドブック-よりよい緩和ケア提供のために. 大阪 : メディカルレビュー社 ; 2011.
 
・ Maddocks I, et al. Palliative Neurology. Cambridge : Cambridge University Press ; 2005. 葛原茂樹, 大西和子 (監訳), 神経内科の緩和ケア-神経筋疾患への包括的緩和アプローチの導入. 大阪 : メディカルレビュー社 ; 2007.
 
・ Oliver D, et al. Palliative Care in Amyotrophic Lateral Sclerosis : From Diagnosis to Bereavement, 2nd edition. NewYork : Oxford University Press ; 2006.
 
P.322 掲載の参考文献
1) Shimizu T, et al. Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis : A multicenter study in Japan. Amyotroph Lateral Scler 2012 ; 13 : 363-366.
PubMed
2) Dupuis L, et al. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 2011 ; 10 : 75-82.
PubMed
3) 桃井浩樹ほか. 本邦における筋萎縮性側索硬化症の病勢経過-厚生省特定疾患神経変性疾患調査研究班調査より. 神経研究の進歩 2004 ; 48 : 133-144.
 
4) Hayashi H, Oppenheimer EA. ALS patients on TPPV : Totally locked-in state, neurologic findings and ethical implications. Neurology 2003 ; 61 : 135-137.
PubMed
5) Shimizu T, et al. Circulatory collapse and sudden death in respirator-dependent amyotrophic lateral sclerosis. J Neurol Sci 1994 ; 124 : 45-55.
PubMed
6) 川田明広ほか. Tracheostomy positive pressure ventilation (TPPV) を導入したALS患者のtotally locked-in state (TLS) の全国実態調査. 臨床神経学 2008 ; 48 : 476-480.
 
7) 中川悠子ほか. 筋萎縮性側索硬化症患者における介護負担とQOLの検討. 臨床神経学 2010 ; 50 : 412-414.
 
8) 内田智久ほか. 筋萎縮性側索硬化症患者における療養形態別の経済的自己負担. 神経治療学 2011 ; 28 : 83-87.
Medical*Online
9) Miyashita M, et al. Care burden and depression in caregivers caring for patients with intractable neurological diseases at home in Japan. J Neurol Sci 2009 ; 276 : 148-152.
PubMed
10) 平野優子. 在宅人工呼吸療法を行うALS患者における身体的重症度別の医療・福祉サービスの利用状況. 日本公衆衛生雑誌 2010 ; 57 : 298-304.
 
11) 吉井絢子, 松田宣子. 保健所保健師に求められる筋萎縮性側索硬化症患者への支援のあり方に関する研究-保健師による支援の現状と課題, 今後の展望に関する一考察. 厚生の指標 2010 ; 57 : 9-16.
 
12) 高田博仁. 障害者自立支援法への対応-医師としての立場から現場における医療面の変化を検討. 医療 2010 ; 64 : 768-771.
Medical*Online
13) 日本ALS協会新潟県支部. 文字盤入門. http://www.jalsa-niigata.com/mojiban1.htm (accessed 1st April, 2013).
 
14) 日本リハビリテーション工学協会. 「重度障害者用意思伝達装置」導入ガイドライン 2012-2013 速報版. http://www.resja.or.jp/com-gl/gl/index.html (accessed 10th May, 2013).
 
15) Ichikawa H, et al. Writing error may be a predictive sign for impending brain atrophy progression in amyotrophic lateral sclerosis : A preliminary study using X-ray computed tomography. Eur Neurol 2011 ; 65 : 346-351.
PubMed
16) Volpato C, et al. Working memory in amyotrophic lateral sclerosis : Auditory eventrelated potentials and neuropsychological evidence. J Clin Neurophysiol 2010 ; 27 : 198-206.
PubMed
・ 吉良潤一 (編). 難病医療専門員による難病患者のための難病相談ガイドブック改訂2版. 福岡 : 九州大学出版会 ; 2011.
 
・ 成田有吾 (編著). 神経難病在宅療養ハンドブック-よりよい緩和ケア提供のために. 大阪 : メディカルレビュー社 ; 2011.
 
P.328 掲載の参考文献
1) Drory VE, et al. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001 ; 191 : 133-137.
PubMed
2) Bello-Haas VD, et al. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology 2007 ; 68 : 2003-2007.
PubMed
3) Francis K, et al. Evaluation and rehabilitation of patients with adult motor neuron disease. Arch Phys Med Rehabil 1999 ; 80 : 951-963.
PubMed
4) Andersen PM, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) : Revised report of an EFNS task force. Eur J Neurol 2012 ; 19 : 360-375.
 
5) 大生定義. リハビリテーションにおけるアウトカム評価尺度Norris Scale, ALSFRS-R, ALSAQ-40. J Clin Rehabil 2006 ; 15 : 364-371.
 
6) ALS治療ガイドライン作成小委員会. 日本神経学会治療ガイドラインALS治療ガイドライン 2002. 臨床神経学 2002 ; 42 : 669-719.
 
7) 中野恭一, 藤原誠. 筋萎縮性側索硬化症. 総合リハビリテーション 1997 ; 25 : 1113-1117.
 
8) 望月廣. 筋萎縮性側索硬化症. 総合リハビリテーション 2005 ; 33 : 721-726.
 
9) 藤本幹雄. リハビリテーション医の対応. Monthly Book Medical Rehabilitation 2009 ; 113 : 25-29.
 
10) 野崎園子ほか. 政策医療ネットワークを基盤にした神経疾患の総合的研究 総括研究報告書 (平成15年度～17年度). 湯浅班嚥下グループのまとめ, 厚生労働省精神・神経疾患研究委託費, 2006, pp.151-164.
 
11) 藤井正吾ほか. 政策医療ネットワークを基盤にした神経疾患の総合的研究 総括研究報告書 (平成15年度～17年度). 筋萎縮性側索硬化症の嚥下障害に対する訓練効果, 厚生労働省精神・神経疾患研究委託費, 2006, pp.100-101.
 
12) 市原典子ほか. ALSにおける嚥下障害の特徴と食事援助法. 神経内科 2003 ; 58 : 285-294.
 
13) 厚生労働省難治性疾患克服研究事業 (平成17年度～19年度) 「特定疾患患者の生活の質 (QOL) の向上に関する研究」班 (主任研究者 中島孝). 筋萎縮性側索硬化症の包括的呼吸ケア指針-呼吸理学療法と非侵襲陽圧換気療法 (NPPV). 2008.
 
14) Pinto S, et al. Respiratory exercise in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012 ; 13 : 33-43.
PubMed
15) 成田有吾. ALS患者へのコミュニケーション支援. 脳21 2012 ; 15 : 69-73.
Medical*Online
16) Bach JR. Amyotrophic lateral sclerosis : Prolongation of life by noninvasive respiratory AIDS. Chest 2002 ; 122 : 92-98.
PubMed
17) Bennett RL, Knowlton GC. Overwork weakness in partially denervated skeletal muscle. Clin Orthop 1958 ; 12 : 22-29.
PubMed
18) Kurtzke JF. Risk factors in amyotrophic lateral sclerosis. Adv Neurol 1991 ; 56 : 245-270.
PubMed
19) Armon C, et al. Epidemiologic correlates of sporadic amyotrophic lateral sclerosis. Neurology 1991 ; 41 : 1077-1084.
PubMed
20) Longstreth WT, et al. Risk of amyotrophic lateral sclerosis and history of physical activity : A population-based case-control study. Arch Neurol 1998 ; 55 : 201-206.
PubMed
P.334 掲載の参考文献
1) 災害時難病患者支援計画策定検討ワーキンググループ (グループリーダー 西澤正豊). 災害時難病患者支援計画を策定するための指針. 厚生労働科学研究費補助金 難治性疾患克服研究事業 重症難病患者の地域医療体制の構築に関する研究班, 2008.
 
2) 災害時要援護者の避難対策に関する検討会. 災害時要援護者の避難支援ガイドライン (改訂版). 内閣府, 2006.
 
3) 東京都福祉保健局保健政策部疾病対策課 (編). 東京都在宅人工呼吸器使用者災害時支援指針. 東京都福祉保健局, 2012.
 
4) 兵庫県健康福祉部健康局疾病対策課 (編). 在宅人工呼吸器装着難病患者災害時支援指針. 兵庫県健康福祉部健康局, 2006.
 
5) 厚生労働省精神・神経疾患研究委託費「筋ジストロフィーの療養と自立支援のシステム構築に関する研究」班 (編). 神経筋難病災害時支援ガイドライン「在宅人工呼吸器装着患者の緊急避難体制」. 2007.
 
6) 安田智美ほか. 在宅神経難病の災害時支援-災害時対応の"常識"が通用しない大規模災害に備えて. 訪問看護と介護 2011 ; 16 : 750-761.
 
7) 今井尚志. 人工呼吸器装着ALS (筋萎縮性側索硬化症) 患者の遠隔地避難. 難病と在宅ケア 2011 ; 17 : 17-20.
Medical*Online
8) 中島孝. 神経難病患者の災害時の対応-二回の地震と東日本大震災への支援経験から. 神経治療学 2012 ; 29 : 207-211.
Medical*Online
9) 日本神経学会. http://www.neurology-jp.org/
 

Case Study

P.340 掲載の参考文献
1) Allgrove J, et al. Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. Lancet 1978 ; 1 (8077) : 1284-1286.
PubMed
2) Houlden H, et al. Clinical and genetic characterization of families with triple A (Allgrove) syndrome. Brain 2002 ; 125 : 2681-2690.
PubMed
3) Tullio-Pelet A, et al. Mutant WD-repeat protein in triple-A syndrome. Nat Genet 2000 ; 26 : 332-335.
PubMed
4) Nakamura K, et al. Adult or late-onset triple A syndrome : Case report and literature review. J Neurol Sci 2010 ; 297 : 85-88.
 
5) Buderus S, et al. Dysphagia due to triple A syndrome : Successful treatment of achalasia by balloon dilatation. Exp Clin Endocrinol Diabetes 2007 ; 115 : 533-536.
PubMed
P.345 掲載の参考文献
1) 湯浅亮一. 痴呆を伴う筋萎縮性側索硬化症について. 臨床神経 1964 ; 4 : 529-533.
 
2) Mitsuyama Y, et al. Presenile dementia with motor neuron disease in Japan : A new entity? Arch Neurol 1979 ; 36 : 592-593.
PubMed
3) Rademakers R, et al. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 2012 ; 8 : 423-434.
PubMed
4) Al-Chalabi A, et al. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol 2012 ; 124 : 339-352.
PubMed
5) 市川博雄ほか. 筋萎縮性側索硬化症と言語障害. BRAIN and NERVE 2010 ; 62 : 435-440.
 
P.350 掲載の参考文献
1) Oda M, et al. A sporadic juvenile case of the amyotrophic lateral sclerosis with neuronal intracytoplasmic inclusions. Acta Neuropathol 1978 ; 44 : 211-216.
 
2) Kusaka H, et al. An adult-onset case of sporadic motor neuron disease with basophilic inclusions. Acta Neuropathol 1990 ; 80 : 660-665.
PubMed
3) Kwiatkowski TJ, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009 ; 323 : 1205-1208.
PubMed
4) Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009 ; 323 : 1208-1211.
PubMed
5) Tateishi T, et al. Multiple system degeneration with basophilic inclusions in Japanese ALS patients with FUS mutation. Acta Neuropathol 2010 ; 119 : 355-364.
PubMed
P.355 掲載の参考文献
1) 安藤哲朗. 頸椎症の診療. 臨床神経 2012 ; 52 : 469-479.
 
2) 亀山隆ほか. ALSと脊椎脊髄疾患の鑑別-症候学から. 脊椎脊髄ジャーナル 2010 ; 23 : 1060-1067.
 
3) Kuwabara S, et al. Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis : Frequency, extent, and specificity. Muscle Nerve 2008 ; 37 : 426-430.
PubMed
4) 角谷彰子ほか. 神経筋電気診断学. Clinical Neuroscience 2012 ; 30 : 1123-1127.
 
5) Yamada M, et al. Amyotrophic lateral sclerosis : Frequent complications by cervical spondylosis. J Orthop Sci 2003 ; 8 : 878-881.
PubMed
6) Keegan JJ. The cause of dissociated motor loss in the upper extremity with cervical spondylosis. J Neurosurg 1965 ; 23 : 528-536.
PubMed
7) 安藤哲朗. 頸椎症性筋萎縮症の症候. 脊椎脊髄ジャーナル 2009 ; 22 : 1104-1109.
 
8) 園生雅弘ほか. True neurogenic thoracic outlet syndrome (TOS) の臨床的・電気生理学的特徴. 臨床神経生理学 2012 ; 40 : 131-139.
Medical*Online
9) 安藤哲朗ほか. Gilliatt-Sumner handを呈した神経性胸郭出口症候群-症例報告と考察. 脊椎脊髄ジャーナル 2012 ; 25 : 601-606.
 
P.360 掲載の参考文献
1) Chance PF, et al. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet 1998 ; 62 : 633-640.
PubMed
2) Rabin BA, et al. Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain 1999 ; 122 (Pt 8) : 1539-1550.
 
3) De Jonghe P, et al. Autosomal dominant juvenile amyotrophic lateral sclerosis and distal hereditary motor neuronopathy with pyramidal tract signs : Synonyms for the same disorder? Brain 2002 ; 125 : 1320-1325.
PubMed
4) Chen YZ, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 2004 ; 74 : 1128-1135.
 
5) Saiga T, et al. Inflammatory radiculoneuropathy in an ALS4 patient with a novel SETX mutation. J Neurol Neurosurg Psychiatry 2012 ; 83 : 763-764.
 

書評

最近チェックした商品履歴

Loading...